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DESIGN AND SYNTHESIS OF NOVEL SCAFFOLDS  
AND BUILDING BLOCKS 
 
Medicinal chemistry focuses on the aspect related to the structural design, synthesis 
and identification of therapeutically interesting compounds, i.e. pharmaceuticals, as 
well as the molecular reasons of their mechanism of action, including the 
understanding of the factors involved in the structure-activity relationships, 
absorption, distribution, metabolism, elimination and toxicity. 
A number of studies have appeared in the recent literature on the identification of 
molecular frameworks, which correspond to the minimum structural subunit, in 
several drugs or lead-compounds, able of providing ligand points for more than one 
type of bioreceptor. Since Evans first introduced the concept of “privileged 
structure”, privileged-based drug discovery has emerged as a fruitful approach in 
medicinal chemistry. Privileged scaffolds increase hit rates for biological targets of 
interest, leading to the discovery of other biologically active targets and generating 
leads with enhanced drug-like properties. Consequently, medicinal chemists value 
privileged structures as core scaffolds for viable starting points in exploration design 
and synthesis.  
Despite the identification of numerous recurring molecular frameworks in bioactive 
molecules, there is a restricted availability of privileged structures. Toward this 
concern, a subject of great fascination and importance, dealing with the need to 
identify novel chemotypes, have been addressed the studies conducted during this 
PhD thesis. Research into drug-like and lead-like concepts has explored a range of 
  
iv 
ideas looking at structural characteristics and physicochemical properties. The 
selected structures might represent potential replacements of frequently occurring 
structural motifs. The development of efficient methodologies for the synthesis of 
the identified compounds has provided the suitable tools to open up an investigation 
about the behaviour of such a kind of molecules towards biological systems. 
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1  PRIVILEGED STRUCTURES 
 
 
The term “privileged structure” has been adopted in several concepts, designing 
compounds highy represented in the overall bioactive compound population, or 
scaffolds able to present functional groups in a favourable arrangement. While 
many classes of privileged compounds such as 1,4-dihydropyridines, biphenyls and 
benzodiazepines produce leads with enhanced drug-like properties, other structures 
such as pyrrolinone compounds were classified as “privileged” since they own rigid 
framework able to direct functional groups in a well defined space.  
Several researches dealing with privileged structures highlighted the reason for 
their privileged status and can help in a more rationale use of these structures in 
drug discovery. This new tool of understanding bioactive molecular diversity is 
employed in the “colonization” of the existing therapeutic space for each molecular 
framework and in association with other classical medicinal chemistry concepts 
assists the rational design of new drug-candidate prototypes. 
1.1 THE DRUG DISCOVERY PROCESS  
 
The traditional process of drug discovery has been driven largely by phenotypic 
observations of the effects of a natural product or a derived synthetic agent on a 
physiological process or pathological state. This was followed by a process of 
iterative synthesis and biological testing. Typically, the molecular nature of the 
biological target was not known, the biological testing was carried out significantly 
in vivo, and chemical synthesis was a hand-crafted ‘one molecule at a time process’. 
It has been a very successful approach yielding antibiotics, antidepressants, 
antihypertensive and anticancer agents, to name but four principal classes of 




This traditional scheme is contrasted with the genomic-based approach where 
genome interrogation was assumed to lead to thousands of new targets, a significant 
increase over the approximately 500 targets in the current pharmacopoeia. 
The advent of genomics and the molecular biology revolution has permitted both the 
definition of new targets and the characterization of the genetic basis of disease 
states. The complexity of human cellular organization is not based upon a simple 
‘one gene = one protein’ model, but rather by multiple use of the same gene-splice 
variants, population alleles and post-translational modification, and by the 
combinatorial diversification of signalling pathways. From this relatively limited 
gene repertoire the human probably expresses in spatial and temporally 
heterogeneous manner some 150,000 proteins. However, a protein target may not be 
druggable because of its intrinsic properties or expression, but also because it may 
play a role in multiple signaling pathways other than the one of pathological interest. 
The deciphering of this signalling network is thus of critical importance to the 
process of target validation. The systems biology approach is an integrated rather 
than a reductionist approach used to understand the relationships between function 
of a biological system and the effects of perturbations such as a disease or the 
addition of a drug or potential drug molecule. This approach suggests that there may 
be only a few thousand druggable targets rather than the 150,000 or so once 
confidently predicted.1 
Presently, GPCRs are the predominant target family addressed, and more than 600 
genes encoding GPCRs have been identified from human genome sequencing 
efforts.2 The balance of such targets and their relative novelty are the domain of the 
companies’ early project-portfolio management strategy.3 Of course, a balance 
always has to be struck between the requirements of the disease area for efficacious 
new therapies, business considerations and, most crucially, the chemical tractability 
or drugability of targets for small-molecule intervention.4 It is well accepted within 
the medicinal chemistry community that, independently of the technology applied, 
certain protein families are more readily modulated by small-molecule intervention 





of hit and lead identification activities. A retrospective analysis of past discovery 
programmes reveals that much higher success rates have been demonstrated for 
aminergic GPCRs compared with large peptide receptors, for example. This is not 
surprising, as modulating protein-protein interactions - often involving large surface 
area- by a small chemical entity is far move demanding than competing against an 
endogenous small-molecule ligand.  
Apart from the intrinsic biochemical and kinetic challenges in identifying an 
appropriate modulator for a target, the range of meaningful assays and  
ligand-identification technologies significantly influences the chances of success. 
High throughput screening (screening of a compound collection to identify hits in an 
in vitro assay, usually performed robotically) is presently the most widely applicable 
technology delivering chemistry entry points for drug discovery programmes. The 
potential for success is nevertheless demonstrated by a variety of development 
candidates and marketed drugs that have resulted from hits generated by HTS 
campaigns. It is evident that in the future the growing number of emerging targets 
will increase the demands put on compound collections and HTS and that this will 
call for new hit and lead generation strategies to curb costs and enhance efficiency.5 
 
1.2 MULTI-PROPERTY OPTIMIZATION 
 
During the past few years, there has been an increasing awareness of the need for 
developing drug-like properties of a molecule. These are the balance of 
biophysicochemical requirements for the molecule to reach its site of action in man 
at the given concentration, for the necessary duration and in an adequate safety 
window in order to answer the therapeutic principle hypothesis.6 
In the past, lead-finding activities were mainly directed towards affinity and 
selectivity rather than molecular properties, metabolic liabilities and so on. It was 
not uncommon for a confirmed single primary active compound to be considered a 
‘lead’ structure, or, in the case of a cluster of activies with SAR, a ‘lead series’. 




perhaps their chemical stability and synthetic accessibility. A consequence of these 
insufficient lead criteria was that full project teams were assembled with only a 
single superficially evaluated ‘lead’. A thorough consideration of other important 
drug features was often postponed later in the optimization phase, when the in vitro 
affinity and selectivity had been fully optimized at the expense of other facets, such 
as solubility, permeability or metabolic stability. 
Unfortunately, as the lead molecules becomes increasingly more potent, selective 
and tailored for the target, there is generally less tolerance for introducing significant 
changes to affect biophysical properties without a large intrinsic affinity penality. 
Such unbalanced, sub-optimal candidates had poor ADME attributes which often 
preclude them from progressing and being fully evaluated in the clinic due to, for 
example, dose-limiting solubility, poor absorption, cytochrome P450 interactions or 
metabolic instability. Clearly, poor initial leads with weak entry criteria into lead 
optimization often can not be refined to generate compounds with an appropriate 
profile, resulting in high attrition rates at the clinical candidate selection stage. This 
point has been highlighted in a recent analysis of launched drugs, which indicates 
that, generally, relatively minor changes in structural and physical molecular 
properties have been made between the lead and the launched drug candidate.7 This 
emphasizes once more that quality of the lead is crucial in most cases to the success 
of the refinement and development process. If the clinical entry criteria are lax, the 
attrition is moved further into pilot safety testing or early clinical-phase studies. The 
optimization process has historically been largely sequential in nature, addressing 
one issue at time, with the hope that all necessary modifications could be 
accommodated within the pharmacophore optimized for affinity only. This approach 
led to a very high and expensive failure rate in the clinic. During the mid-90s, this 
view changed to embrace a more holistic attitude towards lead optimization and 
subsequently to hit-to-lead generation and hit identification. The required trade-off 
for balancing these properties, in conjuction with pure affinity to achieve an 
equilibrated potential therapeutic drug molecule, resulted in a change of approach 





1.3 HIT AND LEAD GENERATION STRATEGIES   
 
The entry point for any chemistry programme within drug discovery research is 
generally the identification of specifically acting low-molecular-weight modulators 
with an adequate activity in a suitable target assay. Such initial hits can be generated 
in a number of ways, depending on the level of information available8 (Figure 1). It 
is therefore important to employ alternative hit-identification strategies that are able 
to tackle a variety of biological macromolecular targets effectively, and to identify 
proprietary, synthetically tractable and pharmacologically relevant compounds 
rapidly. 
These methods can be subdivided into those that require very detailed ligand and/or 
target information, and those that do not. The former include techniques such as 
mutagenesis, NMR and X-ray crystallography, as well as the recognition 
information that can be derived from endogenous ligands or non-natural small 
molecule surrogates retrieved from literature and patents. At the other extreme are 
the technologies that do not require any prior information on target or ligand, and 
which use serendipity-based search strategies in either a given physical or virtual 
compound subset. Example of so called “random” or pseudo-biased hit-
identification strategies include biophysical and biochemical testing that employ one 
or more method of detecting a molecular-binding event, usually in high-throughput 
format9.  
Between these extremes are more integrated approaches, including targeted libraries 
and chemogenomics10. The marriage of HTS with computational chemistry 
methods11 allows for more meaningful and directed iterative rapid-feedback searches 
of subsets and focused libraries. The prerequisite for success of both approaches is 







Figure 1- Hit/lead identification strategies. The most commonly applied hit-identification 
strategies today range from knowledge-based approaches, which use  literature- and patent-
derived molecular entities, endogenous ligands or biostructural information, to the purely 
serendipity-based ‘brute force’ methods such as combinatorial chemistry and high-throughput 
screening 
 
1.4 FOCUSING FOR LIBRARIES 
 
The ‘combinatorial explosion’- meaning the virtually infinite number of compounds 
that are synthetically tractable- has fascinated and challenged chemists ever since the 
inception of the concept. Independent of the library designs, the question of which 
compounds should be made from the huge pool of possibilities always emerges 
immediately, once the chemistry is established and the relevant building blocks are 
identified.12 
The original concept of ‘synthesize and test’, without considering the targets being 




















































nowadays considered to be of much lower interest due to the unsatisfactory hit rates 
obtained so far. The days in which compounds were generated just for filling up the 
companies inventories, without taking any design or filtering criteria into account, 
have passed. Focus has mooved from huge and diverse ‘random’ combinatorial 
libraries towards smaller and focused drug-like subsets. Although the discussion of 
how much focused or biased a library should be is still an ongoing debate, the low 
hit rate of large, random combinatorial libraries, as well as the steady increase in 
demand for screening capacity, has instead set the stage for efforts towards small 
and focused compound collections. 
 
Guided by the target. Biostructural information derived from mutagenesis data, as 
well as NMR or X-ray crystallographic analysis, has long been used for drug 
discovery purposes. Understanding of the mechanism of action of a biological target 
is an important aid in biasing compound collections. These mechanism-based 
libraries have been applied successfully to a variety of proteins to generate 
transition-state mimics using either parallel solution- or solid-phase synthesis 
techniques13. 
 
‘Cherry picking’ from virtual space. A highly sophisticated way to avoid the 
synthesis of trivial analogues is the application of virtual screening tools in order to 
search through chemical space for topologically or pharmacophoric similar entities 
using known actives (seed structures) as references. Biostructural information can 
also be applied if available14. 
 
Privileged structures or motifs. This approach is particularly relevant for targets for 
which very limited or no biostructural informations are available. It is in this case 
where elements of known biologically active molecules are used as “the core” for 
generating libraries encompassing these ‘privileged structures’. One example is 
provided by the benzodiazepine nucleus which is found in ligands of both ion 




for Valium and many other antianxiety and muscle relaxant agents can also be 
directed against other biologically distinct targets (Figure 2).15  
 
 
Figure 2- The benzodiazepine skeleton as a ‘privileged’ structure generating molecules that 
interact at diverse and unrelated targets 
 
The restricted availability of privileged structures clearly limits the scope of this 
ligand-based approach to some extent. As a result, there is a continued need to 
identify novel chemotypes. 
 
1.5 PRIVILEGED STRUCTURES 
 
In summarizing the successful use of benzodiazepines, Evans and colleagues 
concluded that “judicious modification of such structures could be a viable 
alternative in the search for new receptor agonists and antagonists”. In 1988 they 
introduced the term privileged structure in relation to the heterocycle  
1,4-benzodiazepine-2-one, defined as “a single molecular framework able to provide 





improved later by Patchett and Nargund,17 who identified properties in these 
structures that make their interaction with biomacromolecules easier and 
occasionally distinct from the ones that involve the respective endogenous ligands. 
Prior to the seminal paper of Evans coining the privileged structure term, the notion 
of these types of stuctures had been emerging for some time. Early various research 
groups have recognized the presence of recurring structural units in many receptor 
ligands. For example, Ariëns et al. noted the presence of hydrophobic double-ring 
systems in many biogenic amine antagonists, which they suggested must interact 
with accessory hydrophobic binding sites. They also observed multiple actions of 
some molecules and suggested this was related to conformational flexibility.18 
Subsequently, Andrews and Lloyd described a number of common topological 
arrangements for biogenic amine antagonists. They concluded that a common 
pharmacophore existed throughout diverse drug classes, and that specificity resulted 
from secondary binding groups attached to the basic pharmacophore.19  
Priviliged structures need to be distinguished from ‘frequent hitters’ such as those 
described by Roche,20 which either bind nonspecifically to a variety of targets or 
interfere with the read-out of biological assays. Moreover, a structural rather than 
biological definition of a privileged structure was provided by IUPAC as a 
’substructural feature which confers desirable (often drug-like) properties on 
compounds containing that feature. It often consists of a semi-rigid scaffold, which 
is able to present multiple hydrophobic residues without undergoing hydrophobic 
collapse’21.22 
Privileged structures represent an ideal source of lead compounds. A single library 
based upon privileged structures might lead to active compounds at a variety of 
receptors. Several groups have utilized these structures in this manner. For example, 
combinatorial libraries based upon privileged structures have been synthesized by 
Nicolau and colleagues, who utilized a benzopyran scaffold,23,24 Schultz and co-
workers, who made use of the purine scaffold,25,26,27,28 and Hirschmann and Smith, 
who have worked with glycosides.29,30,31 Patchett and co-workers utilized privileged 




proteinaceous surfaces) to which they appended peptide functionality to gain 
specificity.32,33,34 Hirschmann et al. also believed that the attachment of genetically 
encoded and uncoded aminoacid side chains to privilegd structures are a promising 
means to produce diverse libraries of compounds.24 Whereas not every group 
intends to use these scaffolds in such a fashion, several groups have focused on 
privileged structures to improve the efficiency of drug discovery. For example, 
Hirschmann, Smith and colleagues have actively pursued the design and 
development of new privileged scaffolds and have made hybrids of existing 
privileged structures.35  
There has therefore been significant interest in the identification of new privileged 
structures, and many groups have utilized computational procedures to aid this 
endeavor. For example, Nilson et al. explored databases of drugs to identify 
structural motifs that have broad biological activities and developed synthetic 
processes to prepare arrays of such compounds.36 Another example is RECAP, a 
computational technique that has been developed to identify privileged structures 
from biologically active molecules for use in library development.37 Mason et al. 
also developed a four-point pharmacophore method for the design of focused 
combinatorial libraries of molecules with privileged structure characteristics.38 
Natural products can also possess the “privileged structure” characteristics. In 
general, natural products are considered to contain scaffolds with the potentiality to 
be privileged structures because in many cases they are synthesized by biological 
systems to specifically interact with protein targets. Natural products differ from 
synthetic substances under several aspects: they tend to contain fewer nitrogen, 
halogen or sulphur but more oxygen atoms; they are likely to contain a larger 
number of rings and more chiral centers39,40,41; thus natural product scaffolds can be 









1.6 CHARACTERISTICS OF PRIVILEGED STRUCTURES  
 
The understanding of the molecular determinants that underline the privileged 
structure-target relationships should be the key to apply the full potential of the 
privileged structure concept in the design of novel targeted compounds sets. 
However, the reason for which these compounds are “privileged” is not completely 
clear. 
Hirschmann and colleagues have stressed that “no unifying three-dimentional 
structural feature for privileged structures has been identified”. However, 
observations in biology and chemistry fields have suggested those molecules do 
display such characteristics. By the term privileged scaffold it is intendeded a 
substructure or template (sometimes also referred as “motifs” or fingerprings) that 
when incorporated in a pharmacophore has a high degree of drug likeness due to the 
presence of atom or functional group properties that are relevant in ligand binding 
such as: volume, hybridization, partial atomic charge, electronegativity, 
polarizability, hydrophobicity, hydrogen-bonding potential; local properties that are 
often parameterized via the use of global physicochemical properties, such as: 
molecular weight, logP, molar refractivity, and so on. Viable “privileged scaffolds” 
often consist of a relatively rigid ring system, which is able to present multiple 
hydrophobic residues in predictable orientations in space and consequently, without 
undergoing hydrophobic collapse.43 They provide molecular rigidity, allowing less 
entropic energy to be lost upon binding, and also provide better bioavailability. 
Bicyclic and tricyclic scaffolds are therefore an ideal size for compound array. They 
have a small enough molecular weight to provide scope for improved specificity and 
affinity through the attachement of suitable substituents (which will consequently 
increase molecular weight, yet retain drug-like character) in a wide variety of 
topologies. 
The size of privileged structure relative to the entire molecule is an important factor. 
Functional groups such as amides and carboxylic acids are too small and too 




benzene, furan or tiophene are also clearly capable of being privileged structures, 
but when they form part of structures with a molecular weight of around 500 Da, the 
nature and extent of their contribution to the overall molecule is uncertain. However, 
larger structures clearly display all of the characteristics of a privileged structure, if 
on a macromolecular scale. Hence, a privileged structure should constitute a 
significant portion of the total mass of the molecule, and represent its core element. 
Bicyclic and tricyclic compounds are capable of fulfilling these requirements. 
However, it was noted that many privileged structures larger than bicycles were 
merely combination of hybrids of two or more bicyclic privileged structures. Hence, 
bicyclic privileged structures may represent the core elements of an entire suite of 
privileged structures.  
Even in absence of a clear understanding of the reason for this status, the use of 
“privileged structures” provides an empirical alternative to blind screening attempts 
and might represent a useful tool for the development of new, selective compounds 
by its application in structure-based drug design. 
 
1.7 USE OF PRIVILEGED STRUCTURES CONCEPT IN THE 
RATIONAL DESIGN OF NEW CHEMICAL DRUGS 
 
Since the 1990’s, with the use of the combinatorial chemistry and robotyzed 
screening (high throughput synthesis and high throughput screening- HTS), the 
design of new chemical libraries for bioassays has become a great challenge for the 
medicinal chemists, leading to some paradigm changes, especially in the level of 
research conducted in the industrial laboratories. 
It is worth highlighting that, despite the substancial investment made by the 
pharmaceutical industry sector in these new technologies, the discovery of new 
chemical entities (NCEs) that effectively represent an opportunity to reach the 
market as authentic therapeutic innovations, has not fulfilled the expectations of the 





approved by the American regulatory agency (FDA- Food and Drugs 
Administration), with the exception of product with diagnosis purpose, only ca. 50% 
of them had the status of authentic NCEs. 
In this context, the pharmaceutical industrial sector, involved in the research of new 
drugs and medicines, redirected the structural design of collections of synthetic 
derivatives to be bioassayed by HTS, aiming at increasing the probability of 
obtaining new hits candidate to drug prototypes, which presented not only the 
appropriate pharmacophoric requisites, but also adequate solubility properties. The 
development of strategies with this purpose has been widely described in the 
literature and has led to the production of high impact works. Among others, the 
work of Lipinski and collaborators45 described the “rule of the five”, which is an 
excellent working hypothesis for predicting good druglike properties in new 
compounds*. Thus, close attention needs to be paid to molecular weights, as well as 
to the physicochemical properties of lead molecules, such as lipophilicity (logP) and 
aqueous solubility (which will affect oral bioavailability and the feasibility of 
generating a parenteral formulation), together with animal pharmacokinetics, which 
can be extrapolated with caution to predict corresponding behavior in humans. The 
latter is particularly important in providing some assurance that the candidate drug 
molecule will exhibit linear pharmacokinetics in humans, with appropriate dose size 
and elimination characteristics for the intended route and frequency of drug 
administration.  
The employment of the privileged structures concept in the planning of new 
compound sets46,47 has been associated with the use of computational methods and 
pharmacophoric models48,49 or with the fragmentation of bioactive molecules, 
prototype or drugs, and has allowed the identification of relevant structural patterns 
that represent authentic biophores, providing useful frameworks to the building of 
new compound databases50. 
                                                 
*
 In the discovery setting, the rule of five predicts that poor absorption or permeation of drugs 
is more likely when a drug molecule possess either (i) more than 5 hydrogen bond donors, (ii) 
10 hydrogen bond acceptors, (iii) a molecular weight greater than 500, or (iv) a calculated logP 




1.8 BIOISOSTERISM AS GUIDE LINE FOR THE DESIGN OF 
PRIVILEGED STRUCTURES  
 
The principle of bioisosterism has long helped to guide drug discovery. In their 
attempts to optimize lead structures, medicinal chemists intuitively followed the 
principles of Darwinist evolution. The biological activity and, in later stages, the 
target selectivity, toxicology or pharmacokinetic behavior serve as the "fitness 
function" for the "survival" of certain structural entities. Privileged scaffolds contain 
structures, features giving better chances of survival.  
Bioisosterism51 is based on the assumption that "similar" molecules tend to exert 
"similar" biological activities and since long time, medicinal chemists have used this 
concept to modify the structures of biologically active compounds. While similarity 
of chemical structures cannot be defined in an objective manner, bioisosteric 
replacements of atoms or functional groups have paved the way from lead structures 
to therapeutically useful molecules. 
Lead optimization needs similar analogs that cover the chemical space around the 
leads. In this new context, the principle of isosteric replacement of functional groups 
serves as a successful optimization strategy. Its systematic application has resulted 
in a broad variety of therapeutically used drugs, many of them finally having the 
desired combination of favorable properties.52  
To date there is a restricted availability of isosteres of natural motifs and their 
applicability is often limited to a specific lead series SAR. Although novel 
replacements might be identified, their behaviour towards biological systems has 
ultimately to be verified.  
 
1.9 RESEARCH OBJECTIVES  
 
Hit and lead generation are key processes involved in the creation of successful new 





exploration and refinement that largely determined their fate in the later stages of 
clinical development. It is in the early phases of drug discovery that changes in 
process, such as the early interception of key ADME parameters, can have the 
maximum impact on later-stage success and timelines. The present high attrition 
rates, especially after lead-optimization phases, indicate that drug discovery as a 
sequential alignment of independent disciplines is ineffective for delivering high-
quality medicines of the future, and that issues beyond activity and selectivity must 
be addressed as early as possible in a flexible, parallel fashion. Iterative medicinal 
chemistry activities in conjuction with multi-dimensional compound-property 
optimization generate a much-improved basis for proper and timely decisions about 
which lead series to pursue further.   
The research program here described aimed at the identification and synthesis of 
novel bicyclic compounds, able to represent the core elements of an entire suite of 
privileged structures. The program consisted in a first step of design of scaffolds 
which comprised developability characteristics (judged in terms of expected 
metabolic stability and their physicochemical properties). Also consideration of 
literature motifs and drugs in development/market aided the selection of structural 
motifs to investigate. 
In Chapter 2 the synthesis of potential replacements of Ph- and Bn- 
piperazine/piperidine is reported. These heterocycles and their congeners often occur 
in active compounds for aminergic, and non-aminergic, CNS targets. Because of 
their prevalence in the field of pharmacologically active compounds and their drug-
like properties, the synthesis of conformationally restricted analogues could be an 
interesting approach to gain insight into the influence of ring conformation on 
biological activity. 
In Chapter 3 the synthesis of some conformationally restricted amino acids and  
bis-amines is described. Target compounds were designed introducing a further 
constraint in natural cyclic structures and it might be expected that the additional 
conformational rigidity introduced in the molecule could result in improved 
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2  REPLACEMENT of Ph- and Bn- PIPERAZINE/ 
PIPERIDINE 
  
Phenyl- and benzyl- piperazine and piperidine rings are very common structural 
motifs in drug discovery, with a high number encountered in compounds in the 
market. Because of their prevalence in the field of pharmacologically active 
compounds, they are regarded as privileged structural elements for the construction 
of drug-like molecules. For this reason, the synthesis of conformationally restricted 
piperazine/ piperidine analogues could be an interesting approach to gain insight 
into the influence of ring conformation on biological activity. Also modulation of  
N-atom basicity, as well as hindrance around it, are seen as valuable strategies to 
modulate activity at biological target and to influence physicochemical properties, 
selectivity, toxicity and PK characteristics.  
Some examples of such structures are reported in Figure 1.  
 
 
Figure 1 – Examples of replacements of phenyl- and benzyl- piperazine/piperidine  
 
In this chapter the synthetic approach to some of these molecules is reported. The 
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suitable for being used in the preparation of new chemical entities with biological 
activities.  
 
2.1  2- SUBSTITUTED BENZYL PIPERAZINES 
 
The piperazine template already contains some building features and 
pharmacological points and provides potent and selective ligands for a range of 
different biological targets in medicinal chemistry.1 In particular, it is a common 
pharmacophore found in a large number of drugs for the treatment of disorders of 
the central nervous system associated with imbalances in dopaminergic, cholinergic 
or serotonergic signal transmission. Among these, CNS active agents are 
antipsychotics such as bifeprunox (1), antidepressants such as clozapin (2) and 






























The piperazine moiety is also contained in antihypertensive agents such as 
prazosine, calcium channel blockers such as flunarizine (4), H1-blockers such as 
oxatomide, and antidepressant agent befuraline (5). Because of its prevalence in the 
field of pharmacologically active compounds, it is regarded as a privileged structural 
element for the construction of bioactive molecules.2 
Whereas the synthesis of simple 1,4-disubstituted piperazines has received 
considerable attention, only a comparatively small number of C-substituted 
derivatives have been prepared and evaluated for their pharmacological properties.3 
It was found that piperazine derivatives bearing substituents in C-2 position can 
strongly interact with various receptors within the CNS. In Figure 3 some examples 

















k agonist NMDA antagonist σ ligand
 
Figure 3 - C-substituted piperazines 
 
We were interested in preparing a diverse set of 2-substituted piperazines (9a and 
10a) and achieving a suitably flexible synthetic route to allow for the introduction of 
substituents able to modulate the pKa of the basic nitrogen. pKa2 values for benzyl 
piperazine and target compounds were predicted with the ACD/labs software5 
(Figure 4). 




















2-Substituted piperazines are commonly prepared by ring construction and reduction 
of diketopiperazines6,7 or 2-ketopiperazines8, via alkylation and reduction of  
2-methylpyrazines9, or by α-lithiation and alkylation of N-Boc piperazines10. In 
many of these cases, the piperazine derivatives must then be selectively protected 
prior to further modification.11  
We investigated a new synthetic route involving the use of the same protecting 
group to the two nitrogen atoms: the isolation of the only monoprotected compounds 
9a and 10a during the deprotection step could demonstrate the steric and/or 
electronic influence of the side chain on the reactivity of the nitrogen atoms. 
From a retrosynthetic point of view, piperazine ring could be prepared starting from 















Scheme 1 - Retrosynthetic analysis of 9a and 10a 
 
The double alkylation of the N,N’-dibenzylethylendiamine with ethyl  




converted into 13 through controlled ester reduction with DIBAL-H at -78 °C 
followed by double fluorine-substitution with DAST. Both classical catalytic 
hydrogenation conditions and N-deprotection via carbamate (ACE-Cl, DCM then 
MeOH at reflux) gave the monoprotected derivative 9a in satisfactory yield, 
supporting our initial hypothesis. The target compound 9a was obtained in four steps 
































Scheme 2 - Synthesis of difluoromethylenbenzylpiperazine 9a 
 
With a similar synthetic route compound 10a was readly prepared with 46% overall 



























Scheme 3 - Synthesis of 10a 
 
The double alkylation of the N,N’-dibenzylethylendiamine with 3,4-dibromo 
butyronitrile (14) afforded in good yield the full protected piperazine 15, suitable to 
a regioselective deprotection using the methods described above. 
In order to exemplify the possibility of introducing an eventual substituent on the  
N-1, the full deprotection of compounds 9a and 10a was tested. Table 1 summarizes 
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the tested reaction conditions; compounds 9b and 10b were obtained with the 










9a R=CHF2 9b R=CHF2
10a R=CH2CN 10b R=CH2CN
Bn
 
Table 1. N-deprotection reaction conditions 
Entry Conditions Yield (%) 
9a H2, Pd/ C, EtOH   68 
9a H2, Pd/ C, EtOH, AcOOH   61 
9a 1) ACE-Cl, DCE, reflux, 48 h; 2) MeOH, reflux 69 
9a Pd/C, HCOONH4, MeOH, reflux   73 
10a H2, Pd/ C, MeOH, rt      - 
10a 1) ACE-Cl, DCE, 24 h reflux; 2) MeOH, reflux 83 
10a Pd/C, HCOONH4, MeOH, reflux   88 
 
In conclusion, the developed synthetic route has the advantage of not requiring 
orthogonal protection at the two piperazine nitrogen atoms, therefore several 
different 2-functionalized piperazines can be readly prepared starting from the 
simple N,N’-dibenzylethylendiamine. 
 
2.2  ARYL- 2,7-DIAZABICYCLO[3.3.0]OCTANE 
 
The synthesis of polysubstituted and fused pyrrolidines, pyrrolizidines, 
indazolidines, pyranoquinolines and pyrrolo β-carboline ring systems has received 




structural subunits of biologically important alkaloids12 and pharmaceutically 
important compounds.13 Specifically, 2,7-diazabicyclo[3.3.0]octane and its 
derivatives are used as adenosine kinase inhibitors14 and serve as prime 
intermediates in the synthesis of 4-quinolone carboxylic acid and uracil-based 
antibacterials15. Recent studies have also demonstrated the success of racemic  
2,7-diazabicyclo[3.3.0]octane (DABO) as homopiperazine isoster in the context of 
5-HT2C agonism.16 
The wide range of bioactivities of DABO-based systems supported our plan to 
devise a synthetic route to its aryl derivatives that would be able to act as 
replacements of phenyl-piperazine/homopiperazine cores. DABO was selected as 
privileged structure also because of several attractive features: two potential sites (2-
N and 7-N) for attachment to the aryl core (Figure 5), the ability to introduce 












Figure 5 –2,7-Diazabicyclo[3.3.0]octane aryl derivatives 
2.2.1 CHEMISTRY 
 















Scheme 4 - Retrosynthetic analysis  
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The crucial step of the strategy is the well documented [3+2] intramolecular 
cycloaddition of azomethine ylides generated by the decarboxylative condensation 
of amino acids with alkenyl aldehyde 18 (Scheme 4).17,18,19,20 
The desired olefinic aldehyde 18 was synthesized in four steps in excellent yield 
(Scheme 5). Tosylation of allylamine gave sulphonamide 19, which was treated with 
ethyl bromoacetate to afford amino ester 20 in 88% yield. Reduction with DIBAL-H 



































































Condensation of 18 with sarcosine and N-PhGly in refluxing toluene under  
Dean-Stark reaction conditions generated the azomethine ylides which cyclised to 
yield the cis adducts 21 and 22 respectively (Scheme 6). Treatment of compounds 
21 and 22 with magnesium ribbons in MeOH gave respectively the target compound 
16 and the intermediate 24 in good yields. In order to obtain 25, several different 







Table 2 - Aryl amination on the 7-N position of DABO 
Conditions Yields (%) 
Cs2CO3, PhI, Pd(OAc)2, BINAP, Toluene, 100 °C, 28 h   / 
Cs2CO3, PhBr, Pd(OAc)2, BINAP, Toluene, 120 °C mw,1 h / 
K2CO3, PhBr, DMSO, ultrasound  / 
K2CO3, PhBr, DMSO, 100 °C  / 
KOt-Bu, PhBr, DMF, 150 °C, mw   / 
CuI, PhBr, K2CO3,, BINOL, toluene, 120 °C, 22 h   / 
PhB(OH)2, Cu(OAc)2, TEA, Molecular Sieves, DCM, 16h, rt   7 
PhB(OH)2, Cu(OAc)2, TEA, Molecular Sieves, TEMPO, DCM, 16 h, rt   14 
PhB(OH)2, Cu(OAc)2,  Py, Molecular Sieves, TEMPO, DCM, 16 h, rt 17 
PhB(OH)2, Cu(OAc)2, K2CO3,Molecular Sieves, TEMPO, DCM, 16 h, rt 8 
PhB(OH)2, Cu(OAc)2, DBU, Molecular Sieves, TEMPO, DCM, 20 h, rt 9 
PhB(OH)2, Cu(OAc)2, DMAP, Molecular Sieves, TEMPO, DCM, 20 h, rt / 
PhB(OH)2, Cu(OAc)2, DIPEA, Molecular Sieves, TEMPO, DCM, 20 h, rt Traces 
PhB(OH)2, Cu(OAc)2, DIPA, Molecular Sieves, TEMPO, DCM, 20 h, rt 10 
NaH, PhF, DMSO, 20 h, rt or 100°C, 24 h / 
 
As summarized in Table 2, classical Buckwald-Hartwig and Ullmann reaction 
conditions failed; better results were obtained using phenylboric acid in presence of 
Cu(OAc)2 and TEMPO to regenerate the catalyst. The yield of reaction was strongly 
dependent by the nature of the base: pyridine was found the most effective base for 
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our pourpose, even if phenyl derivative 25 was isolated in yield that did not exceed 
17%.  
Our need for large quantities of material led us to pursue a longer synthetic route for 
25 which had the advantage of de novo building of diazabicyclic core already 
functionalized with the phenyl group. The synthesis was carried out starting from the 
intermediate ester 26 prepared as outlined in Scheme 7. 




















Scheme 7 - Synthesis of intermediate 26 
 
Controlled reduction with DIBAL-H failed when applied on the ester 26, therefore 
aldehyde 29 was obtained via reduction to alcohol 30 followed by Swern oxidation. 
Condensation of 29 with sarcosine followed by N-demethylation gave the awaited 
compound 17 in satisfactory yield (Scheme 8). 
The assignment of cis stereochemistry to the ring junctions of all cycloadducts was 
made by analogy with the stereochemistry observed for conventional azomethine 





































In conclusion, it was accomplished an efficient synthesis of two novel octahydro 
aryl-DABO derivatives with high stereoselectivity by tandem ylide generation 
followed by intramolecular trapping by an N-tethered alkenyl group. 
2.3 FUSED AZETIDINES 
 
While fused 2-azetidinones, commonly known as β-lactams, are among the most 
useful azaheterocyclic compounds from both synthetic and medicinal chemistry 
points of view, the potential application of fused azetidines is only partially 
explored. 
Azetidines are an interesting and important class of four membered heterocyclic 
compounds because of their reactivity23 and biological activity24. In the last years 
Jianguo et al.25 have synthesized some nicotinic acetylcholine receptor ligands 
derived from 3,6-diazabicyclo[3.2.0]heptane and demonstrated their potent neuronal 
activity. That study showed the ability of the rigidified –NCCN- motif linker, such 
as 3,6-diazabicyclo[3.2.0]heptanes 32 and 33, in reducing the conformational 
complexity of nicotinic ligands (i.e. nicotine, 31) and in enhancing the ligand 










Figure 6 - Nicotinic acethylcoline receptor ligands 
 
In the light of those results we hypothesized that diazabicyclo[3.2.0]heptane 
framework could be an useful core not only for the optimization of novel selective 
nicotinic acetylcholine receptor ligands, but also for ligands to diverse targets. We 
synthesised 6-phenyl-2,6-diazabicyclo[3.2.0]heptane (34) and 6-phenyl- 
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3,6-diazabicyclo[3.2.0]heptane (35), hypothesizing that the introduction of the 
conformational constraint into the basic backbone could result in enhancing of the 








Figure 7 - Diazabicyclo[3.2.0]heptanes as constrained  phenyl piperazine replacements 
 
2.3.1  6-PHENYL-2,6-DIAZABICYCLO[3.2.0]HEPTANE 
 
From a rapid retrosynthetic analysis, 34 can be derived from azetidinone 36 prepared 
starting from commercially available trans-3-hydroxy L-proline via hydroxamate-




















Scheme 9 - Retrosynthetic analysis 
 
trans-3-Hydroxy L-proline was protected as tert-butylcarbamate and then coupled 
with O-benzylhydroxylamine using the water soluble EDC to afford hydroxamate 39 
in good yield. Cyclization under Mitsunobu reaction conditions gave bicyclic  
































Scheme 10 - Synthesis of the intermediate lactam 37 
 
Direct cleavage of the N-O bond of substituted 2-azetidinones could not be easily 
accomplished using most common N-O bond reduction protocols. The samarium 
diiodide-mediated reduction reported by Romo27 was found unsuccessful. However, 
whilst the catalytic hydrogenolysis of 37 on Pd/C afforded the hydroxylamino 
adduct 40, the reaction carried out using Ni-Ra as catalyst gave in good yield the 













































Scheme 11 – Attempts to obtain 34 
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Unfortunately, all attempts to reduce 41 to amine 42 were unsuccessful. Reduction 
with LiAlH4 in THF or Et2O didn’t work, whereas the treatment with borane-THF 
complex, which quantitatively lead to the full ring opened product 43. 
Hypothesizing that the difficulties associated to the reduction step were due to the 
ability of reductive agents to act as bases instead of as nucleophiles on lactam 41, we 
decided to revert the strategy, first introducing the aromatic side chain on 41 and 
then testing the reduction of the lactam to the corresponding amine 34. 
As showed in Table 3, the use of Buchwald-Hartwig’s reaction conditions in the 
presence of Pd2(dba)3 as catalyst  was found to be essential for the N-arylation, even 
if 44 was isolated in very low yield.   
All attempts to reduce 44 proved ineffective thereby precluding further 










Table 3 -Arylation of the β-lactam 
Conditions Results 
Cu(OAc)2, PhB(OH)2, TEMPO, Py, Molecular sieves, DCM, rt No reaction 
PhBr, DPPF, Pd(OAc)2, t-BuONa, toluene, 120 °C, 48 h Degradation 
Cs2CO3, PhBr, silica gel No reaction 
K2CO3, PhBr, toluene, reflux, 80 h No reaction 
PhBr, rac-BINAP, Pd2(dba)3, t-BuONa, toluene, 100 °C, 10 h 13% 
 
In the light of these problems, we sought an alternative route to the required bicyclic 
amine. trans-3-Hydroxy L-proline was protected as N-Boc amino ester 45b and then  




and unsatured ester 53 in 2:1 ratio. The undesired elimination reaction is particularly 













































































Scheme 12 - Total synthesis of 6-phenyl-2,6-diazabicyclo[3.2.0]heptane 
 
After Staudinger reduction of 47, amino ester 48a was protected as N-Cbz derivative 
and reduced to alcohol. Whilst classical reduction using LiAlH4 in THF failed, 
reduction with DIBAL-H in presence of BH3*Et2O gave amino alcohol 49a in good 
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yield. The alcohol was converted in mesylate 49b, suitable to undergo an 
intramolecular cyclisation to afford the bicyclic bis-amine 50. After N-Cbz 
deprotection, 51 was condensed with bromobenzene via the palladium-mediated 
procedure developed by Buchwald and Hartwig.28 Amination of bromobenzene 
proceeded smoothly and provided the corresponding coupling product with 
moderate chemical yield (32%). The protecting group of the coupling product 52 
was finally removed under acidic conditions (TFA) to afford the target compound 34 
in almost quantitative yield.  
2.3.2 6-PHENYL-3,6-DIAZABICYCLO[3.2.0]HEPTANE 
 
From a retrosynthetic point of view, 35 is straightforwardly disconnected at the C-N 
bond between the phenyl group and fused azetidine. Upon this disconnection,  
























Scheme 13 – Possible approaches to 35 
 
Of the many possible synthetic routes toward 53,29 two different approaches were 
initially chosen for further investigastions: (a) a trans-pyrrolidine approach, 
constructing the azetidine ring from trans-3,4-disubstituted pyrrolidine 55 originally 
reported by Jacquet et al.;30 (b) a cis-pyrrolidine approach, assembling azetidine ring 










































Scheme 14 - Jacquet synthesis of 3,6-diazabicyclo[3.2.0]heptane core 
 
Jacquet et al. reported a synthesis of 3,6-diazabicyclo[3.2.0]heptane core 59 via 
intramolecular cyclization of 3,4-disubstituted N-benzyl pyrrolidine 58 (Scheme 14). 
Their synthesis involved a multistep sequence toward the preparation of 58 and 
required a key ring construction step via C-N bond formation through substitution of 
the mesylate with the primary amino group. The limiting step of that synthesis was 
the inefficient intramolecular displacement of the secondary mesylate 58 with the 
amide ion nucleophile. 
To overcome that problem, we considered translocation of the reacting groups, so 
that ring closure involved more facile displacement of the primary mesylate by the 
secondary amine. This, in turn, required access to the cis-substituted pyrrolidine 56. 
Scheme 15 outlines the synthesis of the intermediate 3,6-diazabicyclo[3.2.0]heptane 
67. Oxime 62 was synthesized through a convenient process31 including the N-Cbz 
protection of 2,2-dimethoxyethylamine and the subsequent N-allylation to offer 
dimethyl acetal 60, hydrolysis of 60 to produce aldehyde 61, and oxime formation 
with hydroxylamine. Intramolecular 1,3-dipolar cycloaddition of oxime 62 afforded 
the cis-racemic intermediate isoxazolidine 63, which was then converted to  
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cis-3-amino-4-(hydroxymethyl)pyrrolidine (64) by reductive cleavage of the N-O 
bond using Zn/HOAc. To minimize the facile air oxidation of 63 to isoxazoline32 
impurities as often detected by LC/MS, cyclization of 62 and reduction of 63 were 
carried out in a single pot providing 64 in 62% overall yield. The optimized six step 
process from 2,2-dimethoxyethylamine to 64 required neither distillation nor 
chromatographic purification. After N-protection, the reaction of 65a with mesyl 
chloride gave 65b, which was smoothly transformed to 67 by removal of the  
N-Boc protecting group under acidic conditions, followed by basification to liberate 
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Monoprotected 3,6-diazabicyclo[3.2.0]heptanes 67 was condensed with 
bromobenzene via the palladium-mediated procedure with a satisfactory yield 
(40%). The protecting group of the coupling product was then removed under 
catalytic hydrogenation conditions (Pd/C, H2) to afford the target compound 35 in 






















Scheme 16 – Derivatization to 35 
 
2.4 AZABICYCLO[3.1.0]HEXANE HETEROCYCLES 
 
3-Azabicyclo[3.1.0]hexane is a basic structure of biologically active natural products 
such as CC-1065,33 duocarmycin,16 and indolizomycin,34 and also a framework of a 
pharmacologically important class of compounds such as 3,4-methanoprolines,35 
poly-L-proline type II peptide mimetics,36 and conformationally rigid analogues of 
[1,4'-bipiperidine]-4'-carboxamides (Figure 8).37 Moreover, recently Renslo has 
reported the synthesis of potential antibacterial bicyclo[3.1.0]hexane derivatives, 
which viewed as conformationally constrained isosters of morpholine-, 
thiomorpholine- and piperazine-substituted phenyloxyoxazolidinones.38 
Due to the good lipophilicity properties and the possibility of several kinds of 
decoration of the molecular framework, 3-azabicyclo[3.1.0]hexane system 
represents an interesting framework for our synthetic activities. 
 
 




Figure 8- Representative pharmacologically important compounds having a  
3-azabicyclo[3.1.0]hexane framework 
 
We engaged in a program aimed at the preparation of several  


















Figure 9 - Azabicyclo[3.1.0]hexane heterocycles 
Halo-compounds are interesting derivatives in the perspective of decorating the 




2.4.1  CHEMISTRY 
 
A survey of literature data shows that the azabicyclo[3.1.0]hexane39 ring system has 
been prepared through intermolecular cyclopropanation of 3-pyrroline or maleimide 
substrates.40 The most direct approach involves rhodium(II) acetate-mediated 
cyclopropanation of an N-protected pyrroline with diazoesters. Unfortunately, these 
reactions often produce mixtures of exo and endo diastereomers and, furthermore, 
could not provide ready access to the desired aryl-substituted cyclopropanes. 
Since the preparation of the more highly oxidized 3-azabicyclo[3.1.0]-hexane- 
2,4-dione systems via reaction of a protected maleimide with a diazoester followed 
by pyrolysis of the resulting pyrazoline had been well reported,41 we decided to 
follow this approach to achieve the exo-stereoselective synthesis of  









Scheme 17 - Retrosynthetic analysis of 3-azabicyclo[3.1.0]-hexane core 
Hydrazones 71a-e were prepared in excellent yields refluxing corresponding 
commercially available aldehydes/ ketones with hydrazine monohydrate. Oxidation 
to diazo derivatives 72 was carried out using a strong excess of MnO2. In a 
preliminary effort, 72a was cycloadditioned to N-benzyl pyrroline; after pyrolysis of 
the resulting pyrazoline, the bicyclic amine 73a was obtained in very modest yield 
(5%). However, using a more electrophilic system, such as the N-benzylmaleimide, 
cycloaddition followed by thermolysis provided pure intermediates 74 in moderate 
to good yields after a simple work up procedure involving slurrying the reaction 
mixture in diethyl ether. Compounds 72d,e needed softer reaction conditions than 
derivatives 72a-c: the cycloaddition already worked at room temperature and the 
heating needed exclusively for the thermolysis step. Adjustment of the succinimide 
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functionality to the desired pyrrolidine was carried out by exhaustive reduction using 
borane-THF complex. The use of LiAlH4 guaranteed the overreduction only of the 
non-iodinate compounds 74a,d. In those conditions partial reduction to derivatives 

















































b R1=I, R2=H, R=CH3
c R1=H R2=I, R=CH3
d R1=R2=R=H
e R1=R=H, R2=I
  R= CH3


















Scheme 18 - Synthesis of 3-azabicyclo[3.1.0]-hexane framework 
 
Compound 73f was readly obtained through p-ioduration of 73d with NIS and 
















Scheme 19 - Derivatization through p-ioduration 
 
Isolation of only one cyclopropane isomer for all isolated compounds led to tentative 
assignment of the phenyl ring to the less hindered exo face. For compounds 74d,e 
and 73f the assignment was supported by a 3.2 Hz coupling constant between the  
H-6 and H-1/H-5. For compounds 73a-c the exo stereochemistry is confirmed by the 
clear NOE effect between the hydrogen atoms of methyl group and H-2endo/ 





















Figure 9 - Stereochemistry assignment 
 
As pyrrolidine nitrogen required eventual deprotection, it was tested the  
N-debenzylation reaction on 73a and 73d samples. The N-deprotection step was not 
so easy as expected, because both 69a and 70a underwent a fast ring opening to give 
monocycles 76 (Scheme 20). 
 


















Scheme 20 - N-Debenzylation  
 
Several attempts were made in order to isolate the deprotected amines 69a and 70a. 
Optimization efforts included reaction conditions and purification methods 
screening. Table 3 summarizes the results obtained for 73a: in all cases of successful 
deprotection 1H NMR analysis showed a mixture of 69a and 76a. Moreover, it was 
observed that the use of silica gel as stationary phase for chromatographic 
purification promoted the further degradation of 69a probably due to its acidity. We 
found that the use of neutral florisil as stationary phase allowed the purification of 
69a and arrested the ring opening process.  
These optimized working conditions were then tested on compound 73d: the 
treatment with NH4+HCOO- in presence of Pd/C followed by purification over 
florisil allowed to isolate amine 70a in good yield (69%).  
 
Table 3 - N-Debenzylation of 73a: tested conditions 
Reaction conditions Purification Yields of 69a (%) 
H2, Ni/Ra, EtOH - - 
AlCl3, benzene, reflux - - 
H2, Pd/C, MeOH, 65 °C Florisil 30% 
1) ACE-Cl, DCE, reflux, 48h; 2) MeOH, reflux Silica gel Degradation of TM 
1) ACE-Cl, DCE, reflux, 48h; 2) MeOH, reflux Florisil 20% 
NH4+HCOO- (5 eq), Pd/C, MeOH, room temperature - - 
NH4+HCOO- (3 eq), Pd/C, MeOH, reflux Silica gel Degradation of TM 





2.5  EXPERIMENTAL SECTION 
All moisture-sensitive reactions were performed under argon or nitrogen atmosphere 
using oven-dried glassware. All chemicals and solvents were purchased from 
commercial sources and used without purification, unless otherwise noted. 1H and 
13C NMR spectra were recorded either on Varian instruments at 200, 400, 500 or 
600 MHz  or on Bruker instruments at 400 MHz and 50, 100, 125 or 150 MHz or 
125 Mz, respectively. Solvent was CDCl3 unless otherwise specified. Mono- (1H and 
1H with homonuclear decoupling) and two-dimensional techniques (1H–1H COSY, 
1H–1H ROESY, 1H-13C HSQC) were used for stereochemistry investigation. 
Chemical shifts are reported in ppm (δ) using the residual solvent line as internal 
standard. The NMR spectra were recorded at a temperature ranging from 25 to  
90 ºC. When more than one conformer was detected the chemical shifts for the most 
abundant one is usually reported. Mass spectra (MS) were taken on a Micromass 
ZMD 2000 Mass Spectrometer, operating in ES (+) ionization mode. Total ion 
current (TIC) and DAD UV chromatographic traces together with MS and UV 
spectra associated with the peaks were taken on a UPLC/MS AcquityTM system 
equipped with 2996 PDA detector and coupled to a Waters Micromass ZQTM mass 
spectrometer operating in positive or negative electrospray ionisation mode. [LC/MS 
- ES (+/-): analyses performed using an AcquityTM UPLC BEH C18 column (50 x 
2.1 mm, 1.7 µm particle size), column temperature 40 ºC, mobile phase: A -water + 
0.1% HCOOH / B - CH3CN + 0.06% HCOOH, Flow rate: 1.0 mL/min, Run time= 
1.5 min, Gradient: t=0 min 3% B, t=0.05 min 6% B, t= 0.57 min 70% B, t=1.06 min 
99% B, t=1.449 min 99% B, t=1.45 min 3% B, stop time 1.5 min. Positive ES 100-
1000, Negative ES 100-800, UV detection DAD 210-350nm. The usage of this 
methodology is indicated by “UPLC/MS” in the analytic characterization of the 
described compounds. Unless otherwise specified, preparative HPLC-MS 
conditions, indicated by “HPLC/MS” – basic method: Column: Gemini C18 AXIA, 
50 x 21 mm, 5 µm; mobile phase: A: 10 mM aq. NH4HCO3+ ammonia (pH 10); B: 
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CH3CN; Gradient: specified each time, Flow rate: 17 ml/min; UV range: 210-350 
nm; Ionization: ES+/-; Mass range: 100-900 amu. The fractions so obtained are 
typically evaporated to give the compound as free base. For reactions involving 
microwave irradiation, a Personal Chemistry EmrysTM Optimizer was used. For 
some hydrogenations, a H-Cube Tutor™ reactor was used. Chromatography was 
carried out on silica gel 70-230 mesh (supplied by Merck AG Darmstadt, Germany) 
or florisil 60-100 mesh (supplied by Fluka AG Buchs, Switzerland). Flash 
chromatography was carried out on silica gel 230-400 mesh (supplied by Merck AG 
Darmstadt, Germany). In a number of preparations, purification was performed 
using Vac Master systems. SPE-SCX cartridges are ion exchange solid phase 
extraction columns supplied by Varian. The eluent used with SPE-SCX cartridges is 
methanol followed by 2N ammonia solution in methanol. SPE-Si cartridges are 
silica solid phase extraction columns supplied by Varian. 
 
Compound 11. A solution of DIPEA (4.73 mL, 27.2 mmol) and  
N,N’-dibenzylethylendiamine (2 mL, 8.5 mmol) dissolved in 13.5 mL of dry toluene 
was added portionwise to a solution of ethyl 2,3-dibromopropionate (2.48 mL, 17.0 
mmol) in 20 mL of dry toluene warmed to 50 °C. The mixture was heated to reflux 
for 21 h, then cooled to room temperature and filtered from the solid. Organic layer 
was evaporated under vacuum and the crude residue purified by chromatography 
over silica gel (grad. Etp to Etp/Et2O= 85:15) to afford the pure 11 (2.68 g, 93%). 1H 
NMR (400 MHz) δ 7.22-7.34 (m, 10H), 4.08-4.20 (m, 2H), 3.92 (d, J= 13.6 Hz, 
1H), 3.48-3.62 (m, 2H), 3.38 (d, J= 13.2 Hz, 1H), 3.24-3.35 (m, 1H), 3.02-3.12, (m, 
1H), 2.59-2.80, (m, 2H), 2.38-2.57 (m, 3H), 1.24 (t, J= 7.2 Hz,  3H). 
 
Compound 12. 25% wt DIBAL-H solution in toluene (1.58 mL, 2.36 mmol) was 
added dropwise  at – 78 °C to a solution of 11 (400 mg, 1.18 mmol) in 10 mL of dry 
toluene. The mixture was stirred at that temperature for 15 min, then quenched with 




with sat.d aq. NH4Cl solution, dried (Na2SO4) and filtered. Solvent removal under 
reduced pressure afforded 12 (340 mg, 98%), which was used for next step without 
purification.  
 
Compound 13. DAST (365 µl, 2.76 mmol) was added dropwise to a solution of 
aldehyde 12 (340 mg, 1.15 mmol) in 17 mL dry toluene cooled to 0 °C. The mixture 
was gently warmed to reflux; after 3 h the reaction was quenched with sat.d aq. 
NaHCO3 solution, diluted with EtOAc and washed twice with brine. The organic 
layer was dried (Na2SO4), filtered and concentrated under vacuum. Chromatography 
of the crude residue over silica gel (grad. Etp to Etp/Et2O=9:1) gave the pure 
difluoro derivative 13 (160 mg, 44%). 1H NMR (400 MHz) δ 7.21-7.36 (m, 10H), 
6.32 (dt, J= 6.0 Hz, J= 56.4 Hz, 1H), 3.91 (dd, J= 2.8 Hz, J= 13.6 Hz, 1H),  3.78 (d, 
J= 14.0 Hz, 1H), 3.52 (d, J= 13.2 Hz, 1H), 3.48 (d, J= 13.2 Hz, 1H), 2.80-2.98 (m, 
2H), 2.67-2.78 (m, 1H), 2.44-2.60 (m, 3H), 2.34-2.40 (m, 1H). 
 
Compound 14. A solution of Br2 (3.1 mL, 59.6 mmol) in 10 mL of CHCl3 was 
added dropwise to a solution of allylcyanide (4.8 mL, 59.6 mmol) in 50 mL of the 
same solvent. After 1 h the organic layer was washed twice with 5N aq. Na2S2O3 
solution, dried (Na2SO4), filtered and evaporated under reduced pressure to afford 14 
(12.3 g, 91%) as a yellow pale oil. 1H NMR (400 MHz) δ 4.27 (m, 1H), 3.90 (dd,  
J= 4.4 Hz, J= 10.8 Hz, 1H), 3.71 (t, J= 10.8 Hz, 1H), 3.22 (d, J= 5.2 Hz, 2H). 
 
Compound 15. A solution of TEA (15.0 mL, 108.2 mmol) and  
N,N’-dibenzylethylendiamine (12.7 mL, 54.1 mmol) in 30 mL of dry toluene was 
added portionwise to a solution of dibromide 14 (12.3 g, 54.1 mmol) in 120 mL of 
the same solvent warmed to 40 °C. The mixture was heated to reflux for 1 h, then 
cooled to room temperature and filtered from the solid. The organic layer was 
evaporated under vacuum and crude residue was treated with EtOH. Piperazine 15 
was isolated as a white solid (13.4 g, 81%). 1H NMR (400 MHz) δ 7.22-7.38 (m, 
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10H), 3.78 (d, J = 13.2 Hz, 1H), 3.52 (d, J= 13.2 Hz, 1H), 3.42-3.50 (m, 2H), 2.96-
3.04 (m, 1H), 2.89 (dd, J= 8.0 Hz, J= 16.4 Hz, 1H), 2.36-2.66 (m, 7H). 
 
Compounds 9a and 10a. ACE-Cl (6.25 mL, 57.4 mmol) was added dropwise to a 
solution of 13 (13.9 g, 44.1 mmol) in dry DCE (50 mL) cooled to 0 °C. The mixture 
was gently heated to reflux. After 2 h volatiles were evaporated in vacuo; the crude 
residue was dissolved in 20 mL of MeOH and the mixture heated to reflux for 1h. 
After cooling to rt, the mixture was filtered from the precipitate and volatiles 
evaporated under vacuum to afford a brown oil. Crystallization from CHCl3/MeOH 
afforded the hydrochloride salt of 9a as white solid (9.59 g, 83%). 1H NMR (400 
MHz) δ 10.03 (bs, 1H), 9.86 (bs, 1H), 7.26-7.41 (m, 5H), 6.41 (t, J= 54.4 Hz, 1H), 
4.10 (d, J= 13.2 Hz, 1H), 3.69 (d, J= 13.2 Hz, 1H), 3.12-3.56 (m, 5H), 3.07 (bd,  
J= 1.68 Hz, 1H), 2.82 (bs, 1H). 
Under analogous reaction conditions, hydrochloride salt of 10a was obtained from 
15 as white solid (66% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.53 (bs, 2H), 7.32-
7.44 (m, 4H), 7.22-7.30 (m, 1H), 4.06 (d, J= 13.6 Hz, 1H), 3.20-3.40 (m, 3H), 3.05-
3.18 (m, 1H), 2.96-3.04 (m, 2H), 2.87 (bs, 2H), 2.66-2.78 (m, 1H),  2.38-2.46 (m, 
1H). 13C NMR (100 MHz, DMSO-d6) δ 137.4, 128.8, 128.2, 127.1, 117.9, 56.1, 
52.4, 45.9, 45.4, 42.1, 18.1. 
 
Compounds 9b and 10b. Method A: Ammonium formate (0.0752 g, 1.19 mmol) 
was added to a mixture of 9a (0.104 g, 0.398 mmol) and Pd/C (0.100 g) in 2 mL of 
MeOH. The reaction was heated to reflux for 2 h. After cooling to room 
temperature, the mixture was filtered on a pad of celite and organic layer evaporated 
under vacuum to afford 9b (0.038 g, 70%) as yellow pale oil. Method B: ACE-Cl 
(143 µl, 1.32 mmol) was added dropwise to a solution of 9a (0.110 g, 0.438 mmol) 
in 7 mL dry DCE cooled to 0 °C. The mixture was gently heated to reflux. After 15 
h volatiles were evaporated in vacuo and the crude residue was dissolved in 10 mL 
MeOH. The mixture was heated to reflux for 1 h, then cooled to room temperature 




obtained as white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.31 (bs, 3H), 6.49 (dt, 
J= 2.8 Hz, J= 53.8 Hz, 1H), 4.17 (m, 1H), 3.62 (d, J= 13.2 Hz, 1H), 3.35-3.57 (m, 
3H), 3.21-3.33 (m, 1H), 3.16 (t, J= 12.8 Hz, 1H). 
Under analogous reaction conditions (method B), dihydrochloride salt of 10b (90% 
yield) was obtained from 10a as white solid. 1H NMR (400 MHz, DMSO-d6) δ 
10.20 (bs, 4H), 3.84-4.00 (m, 1H), 3.15-3.55 (m, 8H).13C NMR (100 MHz, DMSO-
d6) δ 118.0, 48.3, 46.2, 42.5, 41.5, 20.9. 
 
Compound 19. TsCl (19.2 g, 100.9 mmol) was added portionwise to a solution of 
AllNH2 (6.57 mL, 87.7 mmol) in 30 mL of Py cooled to 0 °C. The mixture was 
stirred at room temperature for 3 h, then diluted with EtOAc and washed twice with 
2N aq. HCl solution. Organic layer was dried (Na2SO4), filtered and concentrated 
under vacuum. Purification by chromatography over silica gel (DCM) afforded the 
pure amine 19 (16.2 g, 88%) as yellow solid. 1H NMR (200 MHz) δ ppm 7.76 (d,  
J= 8.0 Hz, 2H), 7.32 (d, J= 8.0 Hz, 2H), 5.71-5.88 (m, 1H), 5.06-5.22 (m, 2H), 4.22 
(bt, 1H), 3.54-3.63 (m, 2H), 2.44 (s, 3H). 
 
Compound 20. K2CO3 (15.9 g, 115.4 mmol) was added portionwise at 0 °C to a 
solution of amine 19 (16.2 g, 77.0 mmol) in 250 mL of acetone. After 10 min ethyl 
bromoacetate (11.1 mL, 100.0 mmol) was added and the mixture was gently warmed 
to room temperature. After 15 h, solvent was evaporated under vacuum and the 
residue was dissolved in DCM. Organic layer was washed twice with water, then 
dried (Na2SO4), filtered and concentrated under vacuum. Purification by 
chromatography over silica gel (DCM) afforded the pure 20 (20.3 g, 88%) as yellow 
pale oil. 1H NMR (200 MHz) δ 7.74 (d, J= 8.2 Hz, 2H), 7.30 (d, J= 8.2 Hz, 2H), 
5.81-5.59 (m, 1H), 5.22 (bs, 1H), 5.11-5.18 (m, 1H), 4.09 (q, J= 7.2 Hz, 2H), 4.02 
(s, 2H), 3.90 (d, J= 6.4 Hz, 2H), 2.43 (s, 3H), 1.20 (t, J= 7.2 Hz, 3H). 
 
Compound 18. 1M DIBAL-H solution in hexane (24.0 mL, 24.0 mmol) was added 
dropwise at –78 °C to a solution of amine 20 (5.95 g, 20.0 mmol) in 40 mL of dry 
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DCM. The mixture was stirred 30 min at -78 °C, then quenched with sat.d aq. 
NH4Cl solution. DCM was added, organic layer was washed twice with sat.d aq. 
NH4Cl solution, dried (Na2SO4), filtered and concentrated under vacuum to afford 
the aldehyde 18  which did not need further purification (4.91g, 97%). 1H NMR (200 
MHz) δ 9.60 (t, J= 1.4 Hz, 1H), 7.71 (d, J= 8.2 Hz, 2H), 7.34 (d, J= 8.2 Hz, 2H), 
5.55-5.82 (m, 1H), 5.11-5.25 (m, 2H), 3.77-3.85 (m, 4H), 2.45 (s, 3H). 
 
Compounds 21 and 22. Sarcosine (1.05 g, 11.8 mmol) was added to a solution of 
aldehyde 18 (2.0 g, 7.9 mmol) in 120 mL of toluene. The mixture was heated to 
reflux under Dean-Stark reaction conditions. After 2.5 h solvent was removed under 
reduced pressure. Purification of the crude residue by chromatography over silica 
gel (grad. Etp to Etp/Acetone=6:4) afforded the pure 21 (1.23 g, 55%). 1H NMR 
(200 MHz) δ 7.70 (d, J= 8.2 Hz, 2H), 7.32 (d, J= 8.0 Hz, 2H), 3.27 (dd, J= 1.2 Hz, 
J= 9.8 Hz, 1H), 3.07 (d, J= 6.2 Hz, 2H), 2.58-3.04 (m, 4H), 2.44 (s, 3H), 2.16-2.34 
(m, 4H), 1.90-2.08 (m, 1H), 1.52-1.73 (m, 1H). 
Under analogous reaction conditions, 22 was obtained (39% yield) by condensation 
of 18 with N-PhGly. 1H NMR (400 MHz) δ 7.65 (d, J= 8.4 Hz, 2H), 7.29 (d, J= 8.4 
Hz, 2H), 7.18-7.22 (m, 2H), 6.72 (t, J= 7.2 Hz, 1H), 6.43 (m, 2H), 4.03-4.09 (m, 
1H), 3.36-3.42 (m, 1H), 3.32 (dd, J= 2.8 Hz, J= 10.4 Hz, 1H), 3.25 (dd, J= 6.4 Hz,  
J= 10.0 Hz, 1H), 3.16-3.21 (m, 3H), 2.88-2.96 (m, 1H), 2.43 (s, 3H), 2.06-2.18 (m, 
1H), 1.86-1.95 (m, 1H). MS (ES+) m/z: found 343.1 [MH+], C19H22N2O2S requires 
342.4. 
 
Compounds 16 and 24. In a flame dried 500 mL two-necked round bottomed flask 
were taken activated Mg turnings (2.86 g, 119 mmol). Tosylamine 22 (1.63 g, 4.77 
mmol) dissolved in 200 mL MeOH was transferred into the reaction flask and the 
mixture was heated to reflux for 3 h. Solvent was evaporated under reduced pressure 
and 300 mL of H2O were added. The mixture was stirred 15 min at room 
temperature, then backextracted three times with CHCl3. Combined organics were 




yellow pale oil (0.448 g, 50% yield) . 1H NMR (400 MHz) δ 7.20-7.25 (m, 2H), 6.71 
(t, J= 8.0 Hz, 1H), 6.59 (d, J= 8.4 Hz, 2H), 3.95-4.01 (m, 1H), 3.48-3.55 (m, 1H), 
3.13-3.22 (m, 1H), 3.06 (d, J= 11.6 Hz, 1H), 2.82-2.95 (m, 4H), 1.96-2.14 (m, 2H), 
1.68-1.82 (m, 1H). 
Under analogous reaction conditions, amine 24 was obtained (69% yield) from 21. 
1H NMR (200 MHz) δ 2.86-2.98 (m, 2H), 2.83-2.54 (m, 3H), 2.43 (dd, J= 4.0 Hz, 
J= 12.2 Hz, 1H), 2.34 (s, 3H), 1.82-2.24 (m, 4H). MS (ES+) m/z: found 127.0 
[MH+], C7H14N2 requires 126.2. 
 
Compound 25. To a 10 mL round bottomed flask were added in sequence 30 mg of 
molecular sieves (4 Å, powdered), PhB(OH)2 (49.7 mg, 0.38 mmol), 1 mL of dry 
DCM, Py (32.2 µL, 0.38 mmol), amine 24 (25.0 mg, 0.2 mmol) dissolved in 2 mL of 
dry DCM, Cu(OAc)2 (3.6 mg, 0.02 mmol) and TEMPO (34.0 mg, 0.218 mmol). The 
reaction was allowed to stir under air at room temperature for 24 h. DCM was added 
and the organic was washed with water and sat.d aq. NH4Cl solution. The organic 
layer was dried (Na2SO4), filtered and concentrated under vacuum. Purification by 
chromatography over silica gel of the crude residue (grad. DCM to DCM/Acetone= 
1:9) afforded pure 25 (7.0 mg, 17%). 1H NMR (400 MHz) δ 7.17-7.23 (m, 2H), 6.70 
(dt, J= 0.8 Hz, J= 7.2 Hz, 1H), 6.63 (dd, J= 0.8 Hz, J= 8.8 Hz, 2H), 3.47 (d, J= 10.0 
Hz, 1H), 3.24-3.35 (m, 2H), 3.08-3.15 (m, 2H), 2.85-2.98 (m, 2H), 2.30-2.45 (m, 
4H), 2.09-2.20 (m, 1H), 1.69-1.81 (m, 1H). MS (ES+) m/z: found 203.1 [MH+], 
C13H18N2 requires 202.3. 
 
Compound 27.  A solution of aniline (5.0 g, 53.7 mmol) in 100 mL of THF 
containing Boc2O (14.1 g, 64.5 mmol) was heated to reflux for 4 h. The solvent was 
removed in vacuo. The crude residue was treated with 7/3 Hexane/Et2O mixture; the 
precipitate was filtered off, rinsed with Hexane and collected. Amine 27 was 
isolated as yellow pale oil (9.06 g, 87%). 1H NMR (200 MHz) δ 7.23-7.39 (m, 4H), 
7.03 (m, 1H), 6.46 (bs, 1H), 1.52 (s, 9H). 
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Compound 28a. NaH (60% oil dispersion 2.06 g, 51.6 mmol) was added 
portionwise at 0 °C to a solution of 27 (9.06 g, 46.9 mmol) in 100 mL of fresh 
distilled DMF. After 10 min AllBr (7.38 g, 61.0 mmol) was added. The suspension 
was stirred 20 min at 0 °C, then warmed to room temperature. After 1.5 h the 
reaction was quenched with MeOH and diluted with EtOAc; the organic layer was 
washed twice with 1N aq. HCl solution, dried (Na2SO4), filtered and concentrated in 
vacuo to afford the pure 28a (9.97 g, 91%) which did not need any purification. 1H 
NMR (200 MHz) δ 7.11-7.38 (m, 5H), 5.89 (m, 1H), 5.16 (dd, J= 1.4 Hz, J= 7.6 Hz, 
1H), 5.06-5.09 (m, 1H), 4.21 (dt, J= 1.8 Hz, J= 5.6 Hz, 2H), 1.43 (s, 9H). 
 
Compound 28b. TFA (120 mL) was added portionwise at 0 °C to a solution of 28a 
(9.97g, 42.8 mmol) in 30 mL of DCM. The mixture was stirred at that temperature 
for 20 min, then heated to reflux for 3 h. Sat.d aq. K2CO3 solution was added until 
neutrality and the aqueous layer was extracted twice with CHCl3. The combined 
organics were dried (Na2SO4), filtered and evaporated under vacuum to afford 28b 
(4.72 g, 83%) which did not need any purification. 1H NMR (200 MHz) δ 7.16-7.28 
(m, 2H), 6.76 (t, J= 7.4 Hz, 1H), 6.43-6.68 (m, 2H), 5.86-6.11 (m, 1H), 5.33 (dd,  
J= 1.4 Hz, J= 17.2 Hz, 1H), 5.21 (dd, J= 1.6 Hz, J= 10.4 Hz, 1H), 3.68-3.87 (m, 
3H). 
 
Compound 26. NaH (60% oil dispersion 1.70 g, 42.6 mmol) was added portionwise 
to a solution of the amine 28b (4.72 g, 35.5 mmol) in 100 mL of fresh distilled DMF 
under argon atmosphere. After 10 min, ethyl bromoacetate (5.11 mL, 46.1 mmol) 
was added. The mixture was stirred 30 min at room temperature, then warmed to  
80 °C. After 2 h the reaction was not complete and no improvements were observed 
after prolonged heating. Sat.d aq. NH4Cl solution was added and the aqueous layer 
was extracted twice with EtOAc. The combined organics were dried (Na2SO4), 
filtered and concentrated in vacuo. Purification of the crude residue by 
chromatography over silica gel (grad. Etp to Etp/Et2O=97:3) gave the pure amine 26 




6.64-6.71 (m, 2H), 5.82-6.01 (m, 1H), 5.16-5.32 (m, 2H), 4.21 (q, J= 7.2 Hz, 2H), 
4.03-4.07 (m, 4H), 1.28 (t, J= 7.2 Hz, 3H). 
 
Compound 30. LiAlH4 (1.04g, 27.4 mmol) was added at 0 °C to a stirring solution 
of 26 (3.0 g, 13.7 mmol) in 45 mL of dry THF. The mixture was stirred 30 min at 
that temperature, then warmed to room temperature. After 1 h, 10% aq. NaOH 
solution was added to quench the reaction and the aqueous layer was extracted twice 
with EtOAc. The combined organics were dried (Na2SO4), filtered and concentrated 
in vacuo to afford the alcohol 30 (2.18 g, 90%) which did not need any purification 
(90%). 1H NMR (200 MHz) δ 7.20 (t, J=7.2 Hz, 2H), 6.67-6.81 (m, 3H), 5.72-5.97 
(m, 1H), 5.19 (bs, 1H), 5.08-5.17 (m, 1H), 3.93-3.99 (m, 2H), 3.80 (t, J= 5.6 Hz, 
2H), 3.50 (t, J= 5.8 Hz, 2H). 
 
Compound 29. DMSO (2.93 mL, 41.0 mmol) was slowly added at – 78 °C to a 
solution of oxalyl chloride (1.60 mL, 18.8 mmol) in 15 mL of dry DCM. The 
mixture was stirred at the same temperature under argon for 30 min. Alcohol 30 
(1.45 g, 8.20 mmol) dissolved in 5 mL of dry DCM was slowly added and the 
resulting mixture was stirred at -78 °C for 1 h. After addition of TEA (4.70 mL), the 
mixture was stirred for 30 min further. The reaction was allowed to stir at room 
temperature for 2 h, then partitioned between CHCl3 and H2O. The organic layer 
was washed with sat.d aq. NH4Cl solution, dried (Na2SO4), filtered and concentrated 
in vacuo to afford the aldehyde 29 (quantitative) which did not need any further 
purification. 
 
Compound 25. Sarcosine (1.40 g, 15.7 mmol) was added to a solution of aldehyde 
29 (1.41 g, 8.0 mmol) in 120 mL of toluene. The mixture was heated to reflux under 
Dean-Stark reaction conditions for 4 h. Sovent was evaporated under reduced 
pressure and the crude residue was purified by chromatography over silica gel (grad. 
DCM/Acetone=95:5 to Acetone) to afford the pure 31 (801.1 mg, 49%) as a red-
brown oil. 1H NMR (400 MHz) δ 7.20 (t, J= 7.2 Hz, 2H), 6.70 (t, J= 7.2 Hz, 1H), 
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6.63 (dd, J= 0.8 Hz, J= 8.8 Hz, 2H), 3.47 (d, J= 10.0 Hz, 1H), 3.24-3.34 (m, 2H), 
3.07-3.15 (m, 2H), 2.84-2.98 (m, 2H), 2.38 (s, 3H), 2.29-2.41 (m, 1H), 1.50-1.82 (m, 
2H). 
 
Compound 17. ACE-Cl (4.32 mL, 39.6 mmol) was added slowly to a solution of 31 
(801.0 mg, 3.96 mmol) in 20 mL of dry DCE cooled to 0 °C. The mixture was 
stirred at room temperature under argon atmosphere for 20 min, then heated to 
reflux. After 4 h the mixture was cooled to room temperature and DIPEA (6.89 mL, 
39.6 mmol) was added. The resulting mixture was heated to reflux for further 3 h. 
Volatiles were evaporated under reduced pressure; the crude residue was dissolved 
in 20 mL of MeOH and heated to reflux.  Volatiles were evaporated under reduced 
pressure to afford hydrochloride salt of 17 (446 mg, 60% yield).  
 
Compound 38. 10% aq. NaOH solution (10.3 mL) was added to a suspension of 
trans-3-hydroxy proline (3.0 g, 22.9 mmol) in 45 mL of a mixture THF/H2O= 2:1. 
Boc2O (5.98 g, 27.5 mmol) was added and the mixture was allowed to stir at room 
temperature for 18 h. Volatiles were evaporated under vacuum; aqueous layer was 
acidificated with 2N aq. HCl solution until pH 2-3 and extracted three times with 
CHCl3. Combined organics were dried (Na2SO4), filtered and concentrated under 
vacuum to afford acid 38 (2.81 g, 53%) which was used in the next step without any 
purification. 1H NMR (200 MHz, CD3OD) δ 4.34-4.43 (m, 1H),  4.12 (d, J= 14.2 
Hz, 1H), 3.46-3.59 (m, 2H), 1.77-2.15 (m, 2H), 1.46, 1.42 (2s, 9H). 
 
Compound 39. HOBT (1.15 g, 8.56 mmol) and EDC (1.63 g, 8.56 mmol) were 
added to a solution of 38 (1.51 g, 6.60 mmol) in 15 mL of dry THF. After 10 min 
BnONH2 (812 mg, 6.60 mmol) was added and the mixture was allowed to stir at 
room temperature for 18 h under argon atmosphere. EtOAc was added, organic layer 
was washed twice with 0.2N aq. HCl solution, then dried (Na2SO4), filtered and 
concentrated under vacuum. The crude residue was purified by chromatography over 




NMR (200 MHz) δ 7.28-7.49 (m, 5H), 4.91 (d, 1H), 4.87 (d, 1H), 4.64-4.78m (m, 
1H), 4.01-4.12 (m, 1H), 3.28-3.46 (m, 2H), 1.67-2.32 (m, 4H), 1.42 (s, 9H). MS 
(ES+) m/z: found 337.5 [MH+], C17H24N2O5 requires 336.4. 
 
Compound 37. DEAD (436 mg, 2.51 mmol) was added at 0 °C to a solution of 39 
(767.4 mg, 2.28 mmol) and PPh3 (658 mg, 2.51 mmol) in 10 mL of dry THF. The 
mixture was stirred 1h at 0 °C, then allowed to warm to room temperature. After  
16 h volatiles were evaporated under vacuum. The crude residue was purified by 
chromatography over silica gel (grad. Etp/EtOAc=9:1 to Etp/EtOAc=1:1) to afford 
the pure 37 (659.1 mg, 91%) as white solid.1H NMR (200 MHz, DMSO-d6) δ 7.35-
7.47 (m, 5H), 4.99 (d, J=11.4 Hz, 1H), 4.92 (d, J=11.4 Hz, 1H), 4.71-4.92 (m, 1H), 
4.23 (t, J= 4.4 Hz, 1H), 3.66-3.84 (m, 1H), 2.89-3.11 (m, 1H), 1.82 (dd, J= 6.4 Hz, 
J= 14.4 Hz, 1H), 1.52-1.73 (m, 1H), 1.39 (s, 9H).  
 
Compound 40. 10% wt Pd/C was added to a solution of 37 (83 mg, 0.261 mmol) in 
4 mL of EtOH. The atmosphere of reaction flask was satured of H2 and the mixture 
stirred for 5 h at room temperature. The catalyst was removed by filtration through a 
pad of celite. Solvent was evaporated in vacuo to afford compound 40 (55 mg, 92%) 
as yellow pale oil. 1H NMR (200 MHz, DMSO-d6) δ 4.68-4.97 (m, 1H), 4.39 (t,  
J= 4.4 Hz, 1H), 3.75-3.87 (m, 1H), 3.20-3.61 (m, 1H), 2.98-3.19 (m, 1H), 2.02 (dd, 
J= 6.2 Hz, J= 13.8 Hz, 1H), 1.57-1.79 (m, 1H), 1.40 (s, 9H). MS (ES+) m/z: found 
173.3 [MH+-56(Boc)], C10H16N2O4 requires 228.2. 
 
Compound 41. 37 (102 mg, 0.320 mmol) was added to a suspension of Ra-Ni in 5 
mL of MeOH. The atmosphere of reaction flask was satured of H2 and the mixture 
stirred for 4 h at room temperature. The catalyst was removed by filtration through a 
pad of celite. Solvent was evaporated in vacuo to afford compound 41 (52.8 mg, 
78%) as yellow pale oil. 1H NMR (200 MHz, DMSO-d6) δ 8.12 (bs, 1H), 4.81-5.04 
(m, 1H), 4.15 (t, J= 4.4 Hz, 1H), 3.74-3.92 (m, 1H), 3.01-3.22 (m, 1H), 1.78 (dd,  
J= 6.4 Hz, J= 13.8 Hz, 1H), 1.58-1.78 (m, 1H), 1.39 (s, 1H). 
Replacement of Ph- and Bn- piperazine/piperidine 
 
53
Compound 44. A mixture of amide 41 (150 mg, 0.707 mmol), PhBr (0.112 mL, 1.06 
mmol) and tBuONa (102 mg, 1.06 mmol) in 5 mL of dry toluene was degasses and 
purged with argon three times before the addition of BINAP (26.4 mg, 0.042 mmol) 
and Pd2(dba)3 (13 mg, 0.014 mmol). The mixture was heated to 100 °C and stirred at 
that temperature for 10 h. After cooling to room temperature, EtOAc was added and 
organic layer was washed with H2O, dried (Na2SO4), filtered and concentrated under 
vacuum. The crude residue was purified by chromatography over silica gel (CHCl3) 
to afford phenyl derivative 44 (27 mg, 13%) as yellow pale oil. 1H NMR (200 MHz) 
δ 7.18-7.57 (m, 5H), 5.09-5.48 (m, 1H), 4.68 (t, J= 4.6 Hz, 1H), 3.97-4.13 (m, 1H), 
3.19-3.38 (m, 1H), 2.25 (dd, J= 5.8 Hz, J= 13.6 Hz, 1H), 1.72-1.95 (m, 1H), 1.49 (s, 
9H). MS (ES+) m/z: found 233.4 [MH+-56(Boc)], C16H20N2O3 requires 288.3. 
 
Compound 45a. SOCl2 (916 µL) was gradually added at 0 °C to a solution of  
trans-3-hydroxy proline (1.50 g, 11.4 mmol) in 10 mL of MeOH. The mixture was 
heated to reflux for 2.5 h, then stirred at room temperature for 16 h. Volatiles were 
evaporated under vacuum to afford hydrochloride salt of 45a (2.16 g, quantitative) 
as white solid. 1H NMR (200 MHz, DMSO-d6) δ 4.41-4.52 (m, 1H), 4.12 (bs, 1H), 
3.74 (s, 3H), 3.29 (bt, J= 7.8 Hz, 2H), 1.78-2.04 (m, 2H). MS (ES+) m/z: found 
145.9 [MH+], C6H11NO3 requires 145.1. 
 
Compound 45b. Boc2O (3.11 g, 14.26 mmol) was added portionwise to a solution of 
45a (2.16 g, 11.9 mmol) and TEA (3.32 mL, 23.8 mmol) in 40 mL of DCM. The 
mixture was stirred at room temperature for 4 h, then DCM was added and the 
organic phase was washed twice with sat.d aq. NH4Cl solution. The organic layer 
was dried (Na2SO4), filtered and concentrated under vacuum to afford 45b (2.40 g, 
82%) as white solid. 1H NMR (200 MHz) δ 4.37-4.48 (m, 1H), 4.17, 4.29 (2bs, 1H), 






Compound 46. MsCl (1.52 mL, 19.6 mmol) was gradually added at 0 °C to a 
solution of 45b (2.40 g, 9.8 mmol) and TEA (2.0 mL, 19.6 mmol) in 25 mL of dry 
DCM. The mixture was stirred 20 min at 0 °C, then warmed to room temperature for 
3.5 h. DCM was added and organic layer was washed twice with sat.d aq. NH4Cl 
solution, dried (Na2SO4), filtered and concentrated under vacuum. The crude residue 
was purified by chromatography over silica gel (grad. DCM to DCM/ Acetone=9:1) 
to afford 46 (3.03 g, 96%) as white solid. 1H NMR (200 MHz) δ 5.18-5.22 (m, 1H), 
4.46, 4.58 (2s, 1H), 3.44-3.80 (m, 5H), 3.09 (s, 3H), 2.18-2.36 (m, 2H), 1.42, 1.47 
(2s, 9H). 
 
Compound 48a. NaN3 (241 mg, 3.71 mmol) was added to a solution of 46 (1.0 g, 
3.10 mmol) in 12 mL of dry DMF. The mixture was heated to 100 °C for 7 h. After 
cooling to room temperature, EtOAc was added and the organic layer was washed 
twice with sat.d aq. NH4Cl solution, then dried (Na2SO4), filtered and concentrated 
under vacuum to afford a crude mixture of 47 and 53 (728 mg) in 2:1 ratio as 
detected by 1H NMR analysis. 
PPh3 (911 mg, 3.48 mmol) was added to a stirred emulsion of that material (728 mg, 
2.68 mmol) in 13.2 mL of a THF/H2O=10:1 mixture. The resulting mixture was 
heated to reflux for 4 h. Volatiles were evaporated under vacuum. The crude residue 
was purified by chromatography over silica gel (grad. CHCl3 to CHCl3/MeOH=8:2) 
to afford the pure 48a (417 mg, 55% over 2 steps). 1H NMR (200 MHz) δ 4.28 (dd, 
J= 7.8 Hz, J= 13.8 Hz, 1H), 3.51-3.86 (m, 5H), 3.23-3.45 (m, 1H), 2.00-2.20 (m, 
1H), 1.68-1.98 (m, 1H), 1.39, 1.43 (2s, 9H). 
 
Compound 48b. CbzCl (312 µL, 2.22 mmol) was added dropwise to a mixture of 
48a (417 mg, 1.71 mmol) in 6 mL of toluene and 1 mL 10% aq. NaOH solution. The 
mixture was stirred at room temperature for 18 h, then EtOAc and H2O were added. 
The phases were separated and the organic was washed with H2O. The organic layer 
was dried (Na2SO4), filtered and concentrated under vacuum. The crude residue was 
purified by chromatography over silica gel (grad. CHCl3 to CHCl3/MeOH=95:5) to 
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afford the pure derivative 48b (607 mg, 94%). 1H NMR (200 MHz) δ 7.25-7.40 (m, 
5H), 5.15 (d, J= 13.6 Hz, 1H), 5.06 (d, J= 13.6 Hz, 1H), 4.80-4.99 (bs, 1H), 4.41-
4.59 (m, 2H), 3.47-3.78 (m, 4H), 3.24-46 (m, 1H), 2.08-2.29 (m, 1H), 1.82-2.07 (m, 
1H), 1.39, 1.44 (2s, 9H). 
 
Compound 49a. 1M DIBAL-H solution in hexane (4.84 mL, 4.84 mmol) was added 
dropwise at – 78 °C to a stirred solution of ester 48b (600 mg, 1.60 mmol) and 
BF3*Et2O (67.2 µL, 0.56 mmol) in 5 mL of dry toluene. The resulting solution was 
stirred 30 min at – 78 °C, then allowed to warm to room temperature and stirred for 
additional 3 h. The reaction was quenched with sat.d aq. NH4Cl solution. The phases 
were separated and the aqueous extracted twice with CHCl3. The combined organics 
were dried (Na2SO4), filtered and concentrated under vacuum to afford the alcohol 
49a (301 mg, 54%). 1H NMR (200 MHz) δ 7.27-7.41 (m, 5H), 5.11 (bs, 2H), 4.70 
(s, 1H), 4.23-4.56 (m, 1H), 3.82-4.03 (m, 2H), 3.58-3.76 (m, 1H), 3.22-3.53 (m, 
2H), 2.04-2.29 (m, 1H), 1.79-2.02 (m, 1H), 1.45 (s, 9H). 
 
Compound 49b. MsCl (130 µL, 1.7 mmol) was added dropwise to a solution of 
alcohol 49a (300 mg, 0.85 mmol) and TEA (238 µL, 1.70 mmol) in 3 mL of dry 
DCM. The mixture was stirred at room temperature for 18 h. DCM was added; the 
organic layer was washed twice with sat.d aq. NH4Cl solution, then dried (Na2SO4), 
filtered and concentrated under vacuum. The crude residue was purified by 
chromatography over silica gel (grad. CHCl3 to CHCl3/Acetone=9:1) to afford the 
pure 49b (170 mg, 46%). 1H NMR (200 MHz) δ 7.27-7.40 (m, 5H), 5.15 (d, J= 13.6 
Hz, 1H), 5.08 (d, J= 13.6 Hz, 1H), 4.05-78 (m, 4H), 3.18-58 (m, 2H), 2.95 (s, 3H), 
1.76-2.32 (m, 2H), 1.46 (s, 9H). 
 
Compound 50. Compound 49b (100 mg, 0.23 mmol) was dissolved in 2 mL of dry 
THF and tBuOK (38.6 mg, 0.345 mmol) was added. The mixture was stirred during 




twice with H2O. The organic layer was dried (Na2SO4), filtered and concentrated 
under vacuum. The crude material was purified by chromatography over silica gel 
(grad. Etp to Etp/ AcOEt=7:3) to afford the pure 50 (37 mg, 48%). 1H NMR (200 
MHz) δ 7.27-7.42 (m, 5H), 5.09 (s, 2H), 4.89 (t, J= 5.4 Hz, 1H), 4.24-4.58 (m, 1H), 
4.02-4.21 (m, 1H), 3.73-3.97 (m, 1H), 3.40-3.59 (m, 2H), 2.08-2.39 (m, 1H), 1.67-
1.82 (m, 1H), 1.44 (s, 9H). MS (ES+) m/z: found 277.4 [MH+-56(Boc)], C18H24N2O4 
requires 332.4. 
 
 Compound 51. 10% Pd/C was added to a solution of 50 (37 mg, 0.11 mmol) in 2.3 
mL of MeOH. The mixture was stirred under H2 atmosphere for 5 h and then filtered 
from the catalyst through a pad of celite. The volatiles were evaporated under 
vacuum to afford amine 51 (26 mg, quantitative). 1H NMR (200 MHz) δ 5.14 (t,  
J= 6.2 Hz, 1H), 4.53-4.78 (m, 2H), 4.38 (dd, J= 6.2 Hz, J= 11.6 Hz, 1H), 3.80-4.05 
(m, 2H), 3.67-3.79 (m, 1H), 2.51 (bdd, J= 5.6 Hz, J= 15.0 Hz, 1H), 1.90-2.19 (m, 
1H), 1.43 (s, 9H). 
 
Compound 60. Step 1: CbzCl (3.15 mL, 27.1 mmol) was added gradually to a 
mixture of aminoacetaldehyde dimethyl acetal (3.0 g, 28.9 mmol) in 15 mL of 
toluene and aq. NaOH (1.5 g, 36.2 mmol, in 7.5 mL of water) at 10-20 °C. After the 
addition was completed, the mixture was stirred at room temperature for 4 h. The 
organic layer was separated and washed with brine. It was then concentrated to 
afford benzyl 2,2-dimethoxyethyl-carboxylate as an oil (3.0 g, 46% yield). 1H NMR 
(300 MHz) δ 7.30 (m, 5H), 5.11 (s, 2H), 4.37 (t, J = 6.0 Hz, 1H), 3.39 (s, 6H), 3.33 
(t, J = 6.0 Hz, 2H). 
Step 2: Under N2, powdered KOH (3.10 g, 55.2 mmol) and triethyl-
benzylammonium chloride (470 mg, 2.06 mmol) were added to a solution of benzyl 
2,2-dimethoxyethylcarbamate (3.0 g, 12.5 mmol) in 50 mL of dry toluene. A 
solution of AllBr (1.43 mL, 16.6 mmol) in 5 mL of toluene was then added dropwise 
over 1 h at 20-30 °C. The mixture was stirred at room temperature for 14 h. The 
reaction was slowly quenched with water at 20-30 °C over 20 min. The organic 
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layer was separated and the aqueous phase was extracted with toluene. The 
combined organic extracts were washed with brine and concentrated to give 60 (2.39 
g, 68%). 1H NMR (300 MHz, CD3OD) δ 7.23 (m, 5H), 5.75 (m, 1H), 5.15 (m, 4H), 
4.45 (m, 1H), 3.97 (d, J = 5.40 Hz, 2H), 3.37 (m, 5H), 3.32 (s, 3H). 
 
Compound 61. A solution of 60 (2.39 g, 8.57 mmol) in formic acid (2.7 mL) was 
stirred under argon at room temperature for 15 h. Most of the formic acid was then 
removed under reduced pressure at 40-50 °C. The residue was extracted with 
EtOAc. The combined extracts were washed with brine until the aqueous phase had 
a pH of 6-7. The organic solution was then concentrated to provide the pure 61 (2.01 
g, 99%). 1H NMR (300 MHz) δ 9.50 (d, J = 6.4 Hz, 1H), 7.45 (m, 5H), 5.75 (m, 
1H), 5.10 (m, 4H), 4.10 (m, 1H), 3.97 (m, 2H), 3.20 (m, 1H). 
 
Compound 62. A solution of NaOAc·3H2O (1.18 g, 8.70 mmol, in 6 mL of water) 
was added to a flask containing the solution of 61 (2.01 g, 8.61 mmol) and 
NH2OH*HCl (754 mg, 10.85 mmol) in MeCN (10 mL) and then stirred at room 
temperature for 20 h. The volatiles were then removed under reduced pressure, and 
the residue was extracted with EtOAc. The combined extracts were washed with 
brine until the aqueous phase had a pH=7. The organic solution was concentrated to 
provide 60 (2.10 g 98%). 1H NMR (300 MHz, CD3OD) δ 7.27-7.36 (m, 6H), 5.62 
(m, 1H), 5.30 (m, 4H), 4.17 (d, J = 4.41 Hz, 1H), 3.98 (d, J = 5.43 Hz, 1H), 3.94 (m, 
2H). 13C NMR (75 MHz, CDCl3) δ 156.1, 155.9, 149.8, 149.4, 147.0, 136.2, 132.8, 
132.6, 128.4, 128.0, 127.8, 118.1, 117.8, 117.5, 117.3, 67.5, 50.8, 50.4, 49.5, 49.0, 
45.4, 45.1, 42.4, 42.0. 
 
Compound 64. A solution of 62 (950.4 mg, 3.83 mmol) in 10 mL of p-xylene was 
stirred under Ar at 130 °C for 10 h. The brown solution was cooled to room 
temperature, and 10 mL of AcOH were then added. Zinc powder (500 mg, 7.65 
mmol) was added gradually at 0 °C. After the addition was completed, the reaction 




by filtration. The organic solution was then stirred with water for 10 min and 
separated. The aqueous layer was extracted with EtOAc. The combined extracts 
were concentrated under reduced pressure. The residue was basified to pH 9-10 by 
cautious addition of sat.d aq. Na2CO3 solution. The precipitated white solid was 
removed by filtration. The aqueous solution was extracted with CHCl3. The 
combined extracts were washed with sat.d aq. Na2CO3 solution and dried (Na2SO4). 
The mixture was then filtered through a short column of diatomaceous earth and 
concentrated to provide 64 (590 mg, 62%) as an oil.1H NMR (300 MHz, CD3OD) 
δ 7.35 (m, 5H), 5.10 (s, 2H), 3.52-3.80 (m, 5H), 3.32 (m, 2H), 2.40 (m, 1H).  
MS (ES+) m/z: found 251.5 [MH+], C13H18N2O3 requires 250.3. 
 
Compound 65a. A solution of 64 (400 mg, 1.6 mmol) in 5 mL of EtOH was basified 
to pH~10 with 10% aq. NaOH solution. Boc2O (523 mg, 2.4 mmol) was cautiously 
added at 10-20 °C. After the addition was completed, it was allowed to stir at 65 °C 
for 4 h. The volatiles were removed under reduced pressure, and the residue was 
extracted with EtOAc. The combined extracts were washed with brine, dried 
(Na2SO4), filtered and concentrated under vacuum to give 65a (482.4 mg, 86%) as a 
solid.1H NMR (400 MHz, CD3OD) δ 7.35 (m, 5H), 5.10 (s, 2H), 4.20 (m, 1H), 3.50-
3.75 (m, 4H), 3.40 (m, 1H), 3.25 (m, 1H), 2.50 (m, 1H), 1.46 (s, 9H). 
 
Compound 65b. A solution of MsCl (0.373 mL, 4.82 mmol) was added to the 
solution of 65a (482.4 mg, 1.93 mmol) and Et3N (0.537 mL, 3.86 mmol) in 3 mL 
dry DCM at 0 °C. The reaction was allowed to warm to room temperature, stirred 
for 1 h and then quenched with water. The organic layer was separated, and the 
aqueous layer was extracted twice with DCM. The combined organics were washed 
with brine, dried (Na2SO4), filtered and concentrated to give 65b (326.7 mg, 16% 
starting from 62) as an oil.1H NMR (300 MHz) δ 7.30 (m, 5H), 5.16 (s, 2H), 4.75 
(m, 1H), 4.10 (m, 2H), 3.70 (m, 2H), 3.40 (m, 2H), 3.08 (s, 3H), 2.80 (m, 1H), 1.46 
(s, 9H). MS (ES+) m/z: found 429.6 [MH+], C19H28N2O7S requires 428.5. 
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Compound 67. A solution of 65b (151 mg, 0.352 mmol) in 1.5 mL of DCM was 
stirred with TFA (0.2 mL) at room temperature for 1 h. It was then concentrated 
under reduced pressure. The residue was dissolved in EtOH (2.5 mL), basified to 
pH~12 with 10% aq. NaOH solution, and stirred at 60°C for 3 h. It was cooled to 
room temperature and concentrated under reduced pressure to remove most of the 
volatiles. The residue was extracted with CHCl3. The combined extracts were 
washed with brine and then passed through a short column of diatomaceous earth. 
The filtrate was concentrated to give 67 (75.4 mg, 72%). 1H NMR (200 MHz, 
CD3OD) δ 7.26-7.45 (m, 5H), 5.16 (s, 2H), 4.45 (t, J= 5.2 Hz, 1H), 3.82 (t, J= 2.6 
Hz, 2H), 3.77 (d, J= 3.4 Hz, 1H), 3.16-3.42 (m, 4H). 
 
Buchwald-Hartwig Coupling Reaction. The mixture of amine (0.325 mmol), 
bromobenzene (0.051 mL, 0.487 mmol), and tBuONa (46.8 mg, 0.487 mmol) in dry 
toluene (3 mL) was degassed and purged with argon three times before the addition 
of rac-BINAP (12.0 mg, 0.019 mmol) and Pd2(dba)3 (5.95 mg, 0.0065 mmol). It was 
then heated to 100 °C and stirred at this temperature for 10 h. After it was cooled 
down to room temperature, it was diluted with EtOAc and washed with brine. 
Products were isolated after chromatographic purification over silica gel. 
Data for compound 52. 32% yield, 1H NMR (200 MHz) δ 7.20 (dd, J= 1.2 Hz,  
J= 8.4 Hz, 2H), 6.75 (t, J= 7.6 Hz, 1H), 6.46 (dd, J= 1.4 Hz, J= 8.8 Hz, 2H), 4.65 (t,  
J= 5.4 Hz, 1H), 4.33-4.59 (m, 1H), 3.77-4.02 (m, 2H), 3.55-3.76 (m, 2H), 2.15 (dd, 
J= 6.4 Hz, J= 13.0 Hz, 1H), 1.73-1.97 (m, 1H), 1.48 (s, 9H). 
Data for compound 68. 40% yield, 1H NMR (200 MHz) δ 7.15-42 (m, 7H), 6.73 (t, 
J = 7.2 Hz, 1H), 6.40 (d, J = 8.4 Hz, 2H), 5.07-5.20 (m, 2H), 4.58 (dd, J = 3.6 Hz,  
J = 6.6 Hz, 1H), 3.94-4.11 (m, 2H), 3.91 (t, J= 7.4 Hz, 1H), 3.63-3.72 (m, 1H), 3.36-
3.51 (m, 1H), 3.11-3.33 (m, 2H). MS (ES+) m/z: found 309.5 [MH+], C19H20N2O2 
requires 308.3. 
 
Compound 34. TFA (250 µL) was added to a solution of 52 (7.1 mg, 0.026 mmol) 




were evaporated under vacuum to afford 34 as its trifluoroacetic salt (7.5 mg, 98%). 
1H NMR (200 MHz, DMSO-d6) δ 9.44 (bs, 1H), 9.09 (bs, 1H), 7.17 (t, J= 7.4 Hz, 
2H), 6.69 (t, J= 7.4 Hz, 1H), 6.48 (dd, J= 1.0 Hz, J= 7.6 Hz, 2H), 4.70 (t, J= 4.6 Hz, 
1H), 4.11-4.60 (m, 1H), 3.33-4.05 (m, 4H), 2.20 (dd, J= 5.6 Hz, J= 14.0 Hz, 1H), 
1.68-1.91 (m, 1H). 
 
Compound 35. A solution of 68 (30 mg) in 2 mL MeOH was stirred with 10% wt 
Pd/C under H2 for 4 h. The catalyst was cautiously removed by filtration through a 
short column of diatomaceous earth. The filtrate was concentrated to give 35 (18.8 
mg, quantitative). 1H NMR (200 MHz) δ 7.19 (t, J= 8.2 Hz, 2H), 6.71 (t, J= 7.2 Hz, 
1H), 6.40 (d, J= 7.8 Hz, 2H), 4.42-4.83 (m, 2H), 3.85 (t, J= 7.6 Hz, 1H), 3.57 (dd,  
J= 2.8 Hz, J= 7.6 Hz, 1H), 3.30 (dd, J = 7.8 Hz, J = 11.8 Hz, 2H), 2.99-3.17 (m, 
1H), 2.77-2.94 (m, 1H), 2.61 (bd, 1H). 
 
Compounds 71a-e. Hydrazine monohydrate (18.3 mL, 37.7 mmol) was added to a 
solution of acetophenone (4.52 g, 37.7 mmol) in 20 mL MeOH. The solution was 
heated to reflux. After 4 h solvent was evaporated under reduced pressure to afford 
71a (4.80 g, 95%) which did not need any purification. 1H NMR (400 MHz) δ 7.63-
7.66 (m, 2H), 7.29-7.38 (m, 3H), 5.36 (bs, 2H), 2.13 (s, 3H). 
Under analogous reaction conditions, 71b was obtained (97% yield) from  
p-iodoacetophenone: 1H NMR (400 MHz) δ 7.66 (dd, J=1.6 Hz, J= 6.8 Hz, 2H), 
7.37 (dd, J= 1.6 Hz, J= 6.8 Hz, 2H), 5.39 (bs, 2H), 2.08 (s, 3H). 
Under analogous reaction conditions, 71c was obtained (95% yield) from  
m-iodoacetophenone: 1H NMR (400 MHz) δ 7.58-7.74 (m, 2H), 7.24-7.28 (m, 1H), 
7.07-7.13 (m, 1H), 5.31 (bs, 2H), 2.15 (s, 3H). 
Under analogous reaction conditions, 71d was obtained (96% yield) from 
benzaldehyde: 1H NMR (400 MHz) δ 7.75 (s, 1H), 7.52-7.56 (m, 2H), 7.25-7.37 (m, 
3H), 5.50 (bs, 2H). 
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Under analogous reaction conditions, 71e was obtained (96% yield) from  
m-iodobenzaldehyde: 1H NMR (400 MHz) δ 7.71-7.75 (m, 1H), 7.61-7.67 (m, 2H), 
7.17-7.21 (m, 1H), 7.08-7.14 (m, 1H), 4.57 (s, 2H). 
 
Compounds 74a-c. MnO2 (14.8 g, 170.0 mmol) was added portionwise at 0 °C to a 
solution of 71a (3.80 g, 28.3 mmol) in 70 mL of dioxane. The mixture was stirred 1h 
at room temperature, then filtered on a pad of celite. To the resulting solution was 
added N-benzylmaleimide (2.64 g, 14.2 mmol) dissolved in 10 mL of dioxane over 
30 min. The mixture was stirred at room temperature for 2 h, then refluxed for 18 h. 
Volatiles were evaporated under vacuum. The crude was treated with MeOH; the 
precipitate was filtered, rinsed with MeOH and collected. 74a was obtained as a 
white solid (1.42 g, 34%). 1H NMR (400 MHz) δ 7.32-7.44 (m, 4H), 7.25-7.31 (m, 
6H), 4.61 (s, 2H), 2.77 (s, 2H), 1.27 (s, 3H).  
Under analogous reaction conditions, 74b (37% yield) was obtained from 71b:  1H 
NMR (400 MHz) δ 7.64 (d, J= 8.4 Hz, 2H), 7.39-7.40 (m, 2H), 7.25-7.30 (m, 3H), 
7.02 (d, J= 8.4 Hz, 2H), 4.58 (s, 2H), 2.71 (s, 2H), 1.22 (s, 3H).  
Under analogous reaction conditions, 74c (26% yield) was obtained from 71c: 1H 
NMR (400 MHz) δ 7.57-7.72 (m, 2H), 7.39-7.48 (m, 2H), 7.24-7.38 (m, 4H), 7.05 
(t, J= 7.8 Hz, 1H), 4.60 (s, 2H), 2.73 (s, 2H), 1.24 (s, 3H). 
 
Compounds 74d,e. MnO2 (19.71 g, 226.4 mmol) was added portionwise at 0 °C to a 
solution of 71d (4.44 g, 37.0 mmol) in 170 mL of DCM. The mixture was stirred 1h 
at 0 °C and further 30 minutes at room temperature, then filtered on a pad of celite. 
Solvent was evaporated under vacuum and residue dissolved in Et2O (100 mL).  
N-Benzylmaleimide (9.35 g, 50.0 mmol) dissolved in 100 mL Et2O was added and 
the mixture was stirred at room temperature for 2 h. Precipitate was filtered off, 
rinsed with Et2O and collected. The solid was dissolved in 50 mL of benzene and the 
reaction mixture heated to reflux for 15 h. Solvent was evaporated under reduced 




as a white solid (3.58 g, 35%). 1H NMR (400 MHz) δ 7.25-7.36 (m, 8H), 7.07 (dd, 
J= 2.0 Hz, J= 7.6 Hz, 2H), 4.57 (s, 2H), 2.76 (d, J= 3.2 Hz, 2H), 2.67 (m, 1H).  
Under analogous conditions, 74e (26% yield) was obtained from 71e: 1H NMR (400 
MHz) δ 7.58-7.64 (m, 1H), 7.44 (bs, 1H), 7.28-7.34 (m, 5H), 7.03-7.05 (m, 2H), 
4.56 (s, 2H), 2.74 (d, J= 3.2 Hz, 2H), 2.58 (t, 1H).   
 
Compounds 73a-e. 1M Borane solution in THF (45.3 mL, 45.3 mmol) was added 
dropwise to a solution of 74a (2.18 g, 7.50 mmol) in 70 mL of dry THF cooled to  
0 °C. The mixture was stirred 2 h at room temperature and then heated to reflux for 
further 2 h. After cooling to 0 °C, piperazine (3.89 g, 45.3 mmol) dissolved in 24 of 
H2O was added and the solution heated to reflux for 18 h. The reaction mixture was 
cooled to room temperature, diluted with H2O and extracted twice with EtOAc. 
Combined organics were washed with brine, dried (Na2SO4), filtered and 
concentrated under vacuum. Chromatography of the crude material over silica gel 
(CHCl3) afforded the pure 73a (1.56 g, 79%). 1H NMR (400 MHz) δ 7.23-7.34 (m, 
9H), 7.14-7.17 (t, 1H), 3.70 (bs, 2H), 3.04 (bd, 2H), 2.88 (bs, 2H), 1.79 (bs, 2H), 
1.60 (s, 3H). 
Under analogous reaction conditions, 73b (75% yield) was obtained  from 74b: 1H 
NMR (400 MHz) δ 7.57 (dd, J= 2.0 Hz, J= 6.4 Hz, 2H), 7.28-7.33 (m, 4H), 7.21-
7.27 (m, 1H), 6.98 (dd, J= 2.0 Hz, J= 6.4 Hz, 2H), 3.69 (bs, 2H),  3.04 (bd, 2H),  
2.84 (bs, 2H), 1.73 (bs, 2H), 1.58 (s, 3H). 
Under analogous reaction conditions, 73c (82% yield) was obtained from 74c: 1H 
NMR (200 MHz) δ 7.57-7.60 (m, 1H), 7.44-7.47 (m, 1H), 7.17-7.33 (m, 6H), 6.98 
(t, J= 7.8 Hz, 1H), 3.66 (s, 2H), 3.04 (d, J= 9.4 Hz, 2H), 2.76-2.84 (m, 2H), 1.71-
1.74 (m, 2H), 1.59 (s, 3H). 
Under analogous reaction conditions, 73d (89% yield) was obtained from 74d: 1H 
NMR (400 MHz) δ 7.33-7.35 (m, 4H), 7.23-7.26 (m, 3H), 7.13-7.19 (m, 1H), 7.05 
(d, J= 8.0 Hz, 2H), 3.68 (s, 2H), 3.15 (bd, J= 8.8 Hz, 2H), 2.52 (bd, J= 8.4 Hz, 2H), 
2.38 (bs, 1H), 1.68 (s, 2H). 
Replacement of Ph- and Bn- piperazine/piperidine 
 
63
Under analogous reaction conditions, 73e (78% yield) was obtained from 74e: 1H 
NMR (200 MHz) δ 7.19-7.53 (m, 7H), 6.85-7.04 (m, 2H), 3.64 (s, 2H), 3.11 (d,  
J= 9.0 Hz, 2H), 2.47 (d, J= 8.6 Hz, 2H), 2.30 (t, 1H), 1.64 (bs, 2H). 
 
Compound 73f. TFMSA (1.01 mL, 11.61 mmol) and NIS (1.22 g, 5.41 mmol) were 
added to a solution of the amine 73d (0.963 g, 3.87 mmol) in 11 mL of acetonitrile 
cooled to 0 °C. The mixture was gradually warmed to room temperature. After 22 h, 
the reaction mixture was quenched with sat.d aq. NaHCO3 solution and extracted 
twice with EtOAc. Combined organics were dried (Na2SO4), filtered and 
concentrated under vacuum. Flash chromatography of the crude residue over silica 
gel (DCM) gave the pure 73f (1.01 g, 69%). 1H NMR (200 MHz) δ 7.53 (d, J= 8.4 
Hz, 2H), 7.20-7.32 (m, 5H), 6.78 (d, J= 8.4 Hz, 2H), 3.64 (s, 2H), 3.11 (d, J= 8.6 
Hz, 2H), 2.47 (bd, J= 8.4 Hz, 2H), 2.30 (t, J= 3.2 Hz, 1H), 1.62 (bs, 2H). 
 
Compounds 69a and 70a. To a suspension of 73a (248 mg, 1.0 mmol) in 50 mL of 
MeOH were added first ammonium formate (189 mg, 3.0 mmol) and then 10% wt 
Pd/C (0.3 mmol). The reaction mixture was heated to reflux for 1 h. The suspension 
was filtered from the catalyst through a pad of celite and solvent evaporated under 
vacuum. Chromatography of the crude residue over florisil (grad. DCM to 
DCM/MeOH=8:2) afforded the pure 69a (88 mg, 51%). 1H NMR (400 MHz) δ 
7.24-7.38 (m, 4H), 7.15-7.22 (m, 1H), 3.28-3.42 (m, 2H), 3.16 (d, J= 8.0 Hz, 2H), 
2.24 (bs, 1H), 1.82-1.95 (m, 2H), 1.37 (s, 3 H). 
Under analogous reaction conditions, 70a (69% yield) was obtained from 73d: 1H 
NMR (400 MHz) δ 7.24-7.31 (m, 2H), 7.12-7.19 (m, 1H), 7.03-7.11 (m, 2H), 3.18 





                                                 
1
 Kumar, A. C. S.; Swamy, S. N.; Thimmegowda, N. R.; Prasad, S. B. B.; Yip, G. W.; 
Rangappa, K. S. Med. Chem. Res. 2007, 16, 179. 
2
 For some examples, see: (a) Cha, M. Y.; Choi, B. C.; Kang, K. H.; Pae, A. N.; Choi, K. I.; 
Cho, Y. S.; Koh, H. Y.; Lee, H. Y.; Jung, D.; Kong, J. Y. Bioorg. Med. Chem. Lett. 2002, 12, 
1327. (b) Goodfellow, V. S.; Laudemann, C. P.; gerrity, J. I.; Burkard, M.; Strobel, E.; Zuzack, 
S.; McLeod, D. A. Mol. Divers. 1996, 2, 97. (c) Herpin, T. F.; Morton, G. C.; Dunn, A. K.; 
Fillon, C.; Menard, P. R.; Tang, S. Y.; Salvino, J. M.; Labaudiniere, R. F. Mol. Divers. 1998, 4, 
221. (d) Lewis, I.; Rohde, B.; Mengus, M.; Weetall, M.; Maida, S.; Hugo, R.; Lake, P. Mol. 
Divers. 2000, 5, 61. 
3
 Opatz, T. Eur. J. Org. Chem. 2004, 4113. 
4
 Bedürftiga, S.; Wünsch, B. European J. Med. Chem. 2006, 41, 387.  
5
 ACD/Labs ACD/pKa DB version 11.0; 11.0 ed.; Advanced Chemistry Development, Inc. 
www.acdlabs.com: Toronto 
6
 For a review, see: (a) Dinsmore, C. J.; Beshore, D. C. Tetrahedron 2002, 58, 3298. For 
leading references, see: (b) Kopple, K.; Ghazarian, H. J. J. Org. Chem. 1968, 33, 862. (c) 
Nitecki, D. E.; Halpern, B.; Westley, J. W. J. Org. Chem. 1968, 33, 864. (d) Grahl-Nielsen, O. 
Tetrahedron Lett. 1969, 2897. (e) Suzuki, K.; Sazaki, Y.; Endo, N; Mihara, Y. Chem. Pharm. 
Bull. 1981, 29, 233. (f) Ueda, T.; Saito, M.; Kato, T.; Izumiya, N. Bull. Chem. Soc. Jpn. 1983, 
56, 568. 
7
 Greenstein, J. P.; Winitz, M. In Chemistry of the Amino Acids; Wiley: New York, NY, 1961; 
Vol. 2, p 793. 
8
 For a review, see: Dinsmore, C. J.; Beshore, D. C. Org. Prep. Proced. Int. 2002, 34, 367. 
9
 For recent example, see: (a) Binisti, C.; Asogba, L.; Touboul, E.; Mounier, C.; Huet, J.; 
Ombetta, J.-E.; Dong, C. Z.; Redeuilh, C.; Heymans, F.; Godfroid, J.-J. Eur. J. Med. Chem. 
2001, 36, 809; (b) Scapecchi, S.; Martini, E.; Manetti, D.; Ghelardini, C.; Martelli, C.; Dei, S.; 
Galeotti, N.; Guandalini, L.; Novella, R. M.; Deodori, E. Bioorg. Med. Chem. 2004, 12, 71. 
10
 Berkheij, M.; van der Sluis, L.; Sewing, C.; den Boer, D. J.; Terpstra, J. W.; Hiemstra, H.; 
Iwema Bakker, W. I.; van den Hoogenband, A.; van Maarseveen, J. H. Tetrahedron Lett. 2005, 
46, 2369. 
11
 Clark, R. B.; Elbaum, D. Tetrahedron 2007, 63, 3057. 
12
 (a) Daly, J. W.; Garraffo, H. M.; Spande, T. F. in Alkaloids: Chemical and Biological 
Perspectives; Pelletier, S. W., Ed.; Pergamon Press: New York, 1999; Vol. 13, pp 1–161. (b) 
Daly, J. W. in The Alkaloids; Cordell, G. A., Ed.; Academic Press: New York, 1998; Vol. 50, 
pp 141–169. (c) Howard, A. S.; Michael, J. P. In The Alkaloids; Brossi, A., Ed.; Academic 
Press: New York, 1986; Vol. 28, p 183. (d) Wrobel, J. T. In The Alkaloids; Brossi, A., Ed.; 
Academic Press: New York, 1985; Vol. 26, p 327. (e) Takahata, A.; Momose, T. in The 
Alkaloids; Cordell, G. A., Ed.; Academic Press: New York, 1993; Vol. 44, p 189. (f) Robins, 
D. J. Nat. Prod. Rep. 1995, 12, 413. (g) Liddell, J. R. Nat. Prod. Rep. 1996, 13, 187. (h) 
Michael, J. P. Nat. Prod. Rep. 1995, 12, 535. 
13
 (a) Patvardhan, S. P.; Joshi, K. S.; Vadlamudi, R. V. S. V.; Desphande, S. G. Ind. J. Pharm. 
Sci. 1998, 60, 384. (b) Gupta, P.; Butler, P.; Shepperson, N. B.; McHarg, A. Eur. J. Pharmacol. 
2000, 398, 73. (c) Sternsfeld, F.; Guibin, A. R.; Jelly, R. A.; Matassa, V. G.; Reeve, A. J.; 
Hunt, P. A.; Beer, M. S.; Heald, A.; Stanton, J. A.; Sohal, B.; Watt, A. P.; Street, L. J. J. Med. 
Chem. 1999, 42, 677. 
14
 Bauser, M.; Delapierre, G.; Hauswald, M.; Flessner, T.; D_Urso, D.; Hermann, A.; 
Beyreuther, B.; De Vry, J.; Spreyer, P.; Reissmuller, E.; Meier, H. Bioorg. Med. Chem. Lett. 
2004, 14, 1997. 
Replacement of Ph- and Bn- piperazine/piperidine 
 
65
                                                                                                       
15
 Petersen, U.; Schenke, T.; Krebs, A.; Grohe, K.; Scheriewer, M.; Haller, I.; Mezger, K. G.; 
Endermann, R.; Zeiler, H. J. U.S. Patent, 5,416,096, 1996; Chem. Abstr. 1996, 124, 289280c. 
16
 Huck, B. R.; Llamas, L.; Robarge, M. J.; Dent, T. C.; Song, J.; Hodnick, W. F.; Crumrine, 
C.; Stricker-Krongrad, A.; Harrington, J.; Brunden, K. R.; Bennani, Y. Bioorg. Med. Chem. 
Lett. 2006, 16, 2891. 
17
 (a) Grigg, R.; Surendrakumar, S.; Thianpatanagul, S.; Vipond, D. J. Chem. Soc., Chem. 
Commun. 1987, 47. (b) Grigg, R.; Idle, J.; McMeekin, P.; Vipond, D. J. Chem. Soc., Chem. 
Commun. 1987, 49. (c) Grigg, R.; Idle, J.; McMeekin, P.; Surendrakumar, S.; Vipond, D. J. 
Chem. Soc., Perkin. Trans. 1 1988, 2703.  
18
 For examples, of intramolecular 1,3-dipolar cycloadditions of azomethine ylides generated 
by the decarboxylation, see: (a) Grigg, R.; Savic, V.; Thronton-Pett, M. Tetrahedron 1997, 53, 
10633. (b) Harling, J. D.; Orlek, B. S. Tetrahedron 1998, 54, 14905. (c) Snider, B. B.; Ahn, Y.; 
Foxman, B. M. Tetrahedron Lett. 1999, 40, 3339. (d) Snider, B. B.; Ahn, Y.; O_Hare, S. M. 
Org. Lett. 2001, 3, 4217. 
19
 Nyerges, M.; Bala´zs, L.; Ka´das, I.; Bitter, I.; Ko¨vesdhi, I.; To¨ke, L. Tetrahedron 1995, 
51, 6783.  
20
 (a) Manikandan, S.; Raghunathan, R. Synth. Commun. 2002, 32, 3587. (b) Amalraj, A.; 
Raghunathan, R. Tetrahedron 2001, 57, 10293. (c) Subramaiyan, G.; Raghunathan, R.; Nethaji, 
M. Tetrahedron 2002, 58, 9075. 
21
 Russel, M. G. N.; Beer, M. S.; Stanton, J. A.; Sohal, B.; Mortishire Smith, R. J.; Castro, J. L. 
Bioorg. Med. Chem. Lett. 1999, 9, 2491. 
22
 (a) Armstrong, P.; grigg, R.; Jordan, M. W.; Malone, J. F. Tetrahedron 1985, 41, 3547. (b) 
Grigg, R.; Duffy, L. M.; Dorrity, M. J.; Malone, J. F.; Rajviroongit, S.; Thornton-Pett, M. 
Tetrahedron 1990, 46, 2213. 
23
 Cromwell, N. H.; Phillips, B. Chem. Rev. 1979, 79, 331; Moore, J. A.; Ayers, R. S. in Small 
Ring Heterocycles, ed. A. Hassner, Wiley, New York, 1983, vol. 2; Davies, D. E.; Storr, R. C. 
in Comprehensive Heterocyclic Chemistry, ed. W. Lwowski, Pergamon,  Oxford, 1984, vol. 7, 
pp. 238–284. 
24
 (a) Okutani, T.; Kaneko, T.; Masuda, K. Chem. Pharm. Bull. 1974, 22, 1490. (b) Kobayashi, 
J.; Cheng, J.; Ishibashi, M.; W¨alchli, M. P.; Yamamura, S.; Ohizumi, Y. J. Chem. Soc., Perkin 
Trans. 1 1991, 1135. (c) Frigola, J.; Torrens, A.;  Castrillo, J.A.;  Mas, J.; Va˜n´ o,  D.; 
Berrocal, J. M.; Calvet, C.; Salgado, L.; Redondo, J.; Garc´ıa-Granda, S.; Valent´ı, V.; 
Quintana, J. R. J. Med. Chem. 1994, 37, 4195. (d) Bannon, A. W.; Decker, M. W.; Holladay, 
M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; 
Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Arneric, S. P. Science 1998, 279, 77. (e) Daly, 
J.W.; Garraffo, H. M.; Spande, T. F.; Decker, M. W.; Sullivan, J. P.; Williams,  M. Nat. Prod. 
Rep.2000, 17, 131. 
25
 Jianguo, J.; Schrimpf, M. R.; Sippy, K. B.; Bunnelle, W. H.; Li, T.; Anderson, D. J.; 
Faltynek, C.; Surowy, C. S.; Dyhring, T.; Ahring, P. K. Meyer, M. D. J. Med. Chem.2007, 50, 
5493. 
26
 Miller, M. J. Acc. Chem. Res. 1986, 19, 49. 
27
 Romo, D.; Rzasa, R. M.; Shea, H. A.; Park, K.; Lanhgenhan, J. M.; Sun, L.; Akheizer, A.; 
Liu, J. O. Am. Chem. Soc. 1998, 120, 12237.  
28
 (a) Muci, A. R.; Buchwald, S. L. Top. Curr. Chem.2002, 219, 131. (b) Hartwig, J. F.  Acc. 
Chem. Res. 1998, 31, 852. 
29
 Jaeger, E.; Biel, J. H. J. Org. Chem. 1965, 30, 740. 
30
 Jacquet, J.-P.; Bouzard, D.; Kiechel, J.-R. ; Remuzon, P.  Tetrahedron Lett. 1991, 32, 1565. 
31
 Schenke, T.; Petersen, U. Preparation of 2,7-diazabicyclo[3.3.0]- octanes as intermediates for 




                                                                                                       
32
 Mzengeza, S.; Whitney, R. A. J. Org. Chem. 1988, 53, 4074. 
33
  (a) Boger, D. L.; Johnson, D. S. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3642. (b) Boger, D. 
L.; Johnson, D. S. Angew. Chem., Int. Ed. Engl. 1996, 35, 1438. (c) Boger, D. L.; Boyce, C. 
W.; Garbaccio, R. M.; Goldberg, J. A. Chem. Rev. 1997, 97, 787.  
34
 (a) Gomi, S.; Ikeda, D.; Nakamura, H.; Naganawa, H.; Yamashita, F.; Hotta, K.; Kondo, S.; 
Okami, Y.; Umezawa, H.; Iitaka, Y. J. Antibiot. 1984, 37, 1491. (b) Yamashita, F.; Hotta, K.; 
Kurasawa, S.; Okami, Y.; Umezawa, H. J. Antibiot. 1985, 38, 58.  
35
  (a) Fowden, L.; Smith, A. Phytochemistry 1969, 8, 437. (b) Fujimoto, Y.; Irreverre, F.; 
Karle, J. M.; Karle, I. L.; Witkop, B. J. Am. Chem. Soc. 1971, 93, 3471.  
36
 Mamai, A.; Madalengoitia, J. S. Org. Lett. 2001, 3, 561.  
37
 Schlag, W.-R.; Vilsmaier, E.; Maas, G. Tetrahedron 1994, 50, 3123. 
38
 Renslo, A. R.; Gao, H.; Jaishankar, P.; Venkatachalam, R.; Gordeev, F. Org. Lett. 2005, 7 
(13), 2627. 
39
 For a review, see: Krow, G. R.; Cannon, K. C. Org. Prep. Proced. Int. 2000, 32, 103. 
40
 (a) Brighty, K. E.; Castaldi, M. J. Synlett 1996, 1097. (b) Braish, T. F.; Castaldi, M.; Chan, 
S.; Fox, D. E.; Keltonic, T.; McGarry, J.; Hawkins, J.M.; Norris, T.; Rose, P. R.; Sieser, J. E.; 
Sitter, B. J.; Watson, H., Jr. Synlett 1996, 1100. 
41
 Mustafa, A.; Zayed, S. M. A. D.; Khattab, S. J. Am. Chem. Soc. 1956, 78, 145. 
 67 
3    CONSTRAINED AMINO ACIDS AND BIS-AMINES 
 
A common strategy in the practice of medicinal chemistry is the introduction of 
conformational constraint in the design of new inhibitor structures.1 The goal is 
tighter and/or more selective binding of the inhibitor to its target. Reducing the 
entropic costs of binding can produce the desired effect, but only if enthalpically 
important contacts are not lost as a result of the structural constraint. The most 
common tactic toward these ends involves the construction of cyclic isosters of 
acyclic structures.1a,b The further constraint of cyclic structures can be achieved 
through the introduction of unsaturation, through fusion to a second ring, or by 
conversion of a (mono)cyclic system into a bicyclic one.1c,d,2 As examples of the 
latter approach, cyclopropyl analogues of non cyclopropyl-group containing 
compounds have been used to modify or even improve the selectivity of biologically 
active compounds and improve the pharmacokinetic and pharmacodynamic 
properties of lead compounds.3,4 
The cyclopropane moiety is a common motif in nature. The importance of 
cyclopropyl-group containing compounds for industrial applications is also 
apparent, reflected for example by the tremendously successful of pharmaceutical 
blockbusters like the antiinfectives ciprofloxacin and moxifloxacin.5 Several natural 
and non-natural products with interesting biological activities comprising a 
cyclopropane moiety are amino acids and bis-amines. Among these, β- and γ-amino 
acids have gained increasing attention over the past years, not only as 
conformationally restricted analogues of natural amino acids in peptide/protein 
synthesis6 but also in terms of developing new synthetic methodology7. Constrained 
bis-amines are also interesting as rigid scaffolds with two nitrogen atoms held at 
well defined distance and could be ranked on the base of their ability to act as 





In view of the biological relevance of these two classes of structures, we prepared 
constrained bicyclic heterocycles. In particular, both constrained amino acids and 
bis-amines could give access to a whole series of azabicyclo heteroaromatic 
derivatives. 
 
3.1 CONSTRAINED AMINO ACIDS 
 
The discovery of substances which mimic the action of the mammalian 
neurotransmitter γ-aminobutyric acid (GABA) at its central receptors may be 
important not only for understanding the characteristics of the receptors but also for 
obtaining potentially-useful therapeutic agents. Nipecotic acid and guvacine 
scaffolds are emerging as novel privileged structures due to their cyclic nature, high 
degree of functionality, and diverse range of biological activity. These cyclic amino 
acids, which may be considered as conformationally restricted GABA analogues, 
display in vitro potent activity as inhibitor of [3H]-GABA uptake.8  On the other 
hand, it has been reported that the isomeric compounds, isoguvacine and 
isonipecotic acid, are specific GABA receptors agonists.9  
The use of conformationally constrained amino acids to probe the binding mode of 
bioactive molecules to their receptors is an approach to the design of highly selective 
and active compounds. Reducing the conformational freedom of a ligand may alter 
the binding affinity of the ligand at a given receptor, the selectivity of the ligand 
between different receptors, and the stability of the ligand with respect to enzymatic 
degradation. Examination of the effect of restricting the conformational freedom of a 
given ligand on these properties may lead to increased insight into the bioactive 
conformation of the ligand and hence ultimately to the generation of more potent 
and selective molecules. 
Thus, we became interested in 3-azabicyclo[4.1.0] heptane-1-carboxylic acid (1) and 
3-aza-bicyclo[4.1.0] heptane-6-carboxylic acid  (2) (Figure 1) as templates for the 
design of new drugs. Imparting additional conformational rigidity to the piperidine 




ring of nipecotic/isonipecotic acids incorporating a cyclopropyl group at C-1/ C-6 
positions could result in improved pharmacokinetic properties of lead compounds. 
 













Figure 1 - Conformationally constrained aminoacids 
 
3.1.1 NIPECOTIC ACID MIMETIC 
 
A survey of literature shows that only one approach to the synthesis of 1 has been 
reported. The key synthetic step was the cyclopropanation of the hydroxymethyl 
tetrahydropyridine 3 using samarium-mercuric amalgam and iodochloromethane 
(Scheme 1).10 
 






Scheme 1 - The reported synthesis of nipecotic acid analogues 
 
In the light of the problems associated with the use of mercuric amalgams, we 




retrosynthetic approach, 1 can be straightforwardly disconnected at the fused 
junctions. Upon this disconnection, arecoline (4a) or its simple derivatives (4b, 5) 




1 4a Pg= Me, R= COOMe
4b Pg= Boc, R= COOMe
 5  Pg=MPM, R= CH2OH
 
Scheme 2 - Retrosynthetic analysis 
 
One of the most widely used methods to introduce a cyclopropane ring from an 
olefin is the Simmons-Smith reaction.11,12 Despite the coordinative potential of a 
neighboring amino group, allylic amines or olefins containing an amino group not 
bearing a chelating group have not been directly applied to the Simmons-Smith 
reaction to the propensity of these compounds to undergo N-ylide formation.13 It 
was, therefore, not surprising that cyclopropanation of arecoline (4a) was 
unsuccessfull using those reaction conditions, due to the preferentially formation of 









Scheme 3  
 
In an effort to alleviate the formation of complexed ammonium ylide, the methyl 
amino protecting group of arecoline was converted into the non nucleophilic  
tert-butylcarbamate group. Unfortunately, all attempts to cyclopropanate 4b were 
unsuccessful.  
As summarized in Table 1, cyclopropanation using diazomethane or a 
dihalomethane as carbene sources failed; the reaction under Corey conditions14 




afforded only traces of 7, as detected by UPLC monitoring, but in all case we were 









Table 1 - Cyclopropanation of 4b 
Conditions Results 
CH2N2, Pd(OAc) 2, Et2O  SM 
CH2N2, Pd(PPh3)4, CH2Cl2 SM 
ZnEt2, CH2I2, DCE   SM 
Zn/ Cu, CH2I2, DCE  SM 
ZnEt2, ClCH2I, DCM   SM 
TMSCHN2, toluene, reflux or hν Different product 
tert-BuOLi, CH2I2, NMP  SM 
(CH3) 3SO+I-, NaH, DMSO Only traces of 7on UPLC 
(CH3) 3SO+I-, NaH, THF Only traces of 7on UPLC 
(CH3) 3SO+I-, BEMP, MeCN Only traces of 7on UPLC 
Dimethylaminophenylsulfoxonium methylide, NaH, DMSO Only traces of 7on UPLC 
Dimethylaminophenylsulfoxonium methylide, NaH, THF Only traces of 7on UPLC 
Dimethylaminophenylsulfoxonium methylide, BEMP, MeCN Only traces of 7on UPLC 
Dimethylaminophenylsulfoxonium methylide, DBU, DCM Only traces of 7on UPLC 
 
Treating 4b with TMSCHN2 in refluxing toluene we did not isolate the awaited 
pyrazoline 8, but the regioisomeric hydrazone 9a, which spontaneously underwent 
desilylation to give 2-pyrazoline 9b (Scheme 4). In the light of the literature data,15 
the tautomerization 8→9a competed with the N2-extrusion, however we expected 
that the share of the latter as a unimolecular reaction growed with increasing the 
temperature. Unfortunately, the N2-extrusion was not observed as neither under 





Scheme 4 - Cyclopropanation with TMSCHN2 
 
Treating 9b with a base, such as K2CO3 in refluxing EtOH we observed hydrolysis 
of the ester group, decarboxylation and finally N2-extrusion to give 12 in very low 




























Scheme 5 - N2-extrusion in basic media 
 
A survey of literature revealed few examples that could provide the 
cyclopropanation of an allylic amine by masking the amine as carbamate in the 
   Table 2. N2-Extrusion 
- neat, 150 °C under vacuum  
SM CH3CN or Toluene, hν  
- neat, mw 250 °C  
SM DMSO, mw, 230 °C  
SM DMF, mw 200 °C, 30 min  
SM Toluene or DMF, reflux 








































absence of a chelating group (OH or OR) under Simmons-Smith conditions.16 To 
overcome the absence of a zinc chelating group, the methyl ester 4b was reduced to 
the corresponding alcohol 5 by simply treatment with LiAlH4. Less than satisfactory 
results were obtained using Denmark’s activated IZnCH2Cl reagent17; several 
different cyclopropanation conditions were also tested, but all our attempts were 
again unsuccessful (Table 3).  
 




Table 3 -Cyclopropanation of 5 
Conditions Results  
CH2N2, Pd(PPh3)4, Et2O SM 
CH2N2, ZnCl2, DCE SM 
ZnEt2 (2eq), ClCH2I (4eq), DCE SM 
Zn/Cu, ClCH2I, THF SM 
AlMe3, CH2I2, DCM, 0 °C Only traces of TM on UPLC 
TMSCHN2, Toluene, reflux  Only traces of TM on UPLC 
TMSCHN2, Toluene, PdCl2, 0 °C Only traces of TM on UPLC 
TMSCHN2, Toluene, 0 °C  Only traces of TM on UPLC 
TMSCHN2, CH2Cl2, 0 °C  Only traces of TM on UPLC 
TMSCHN2, Toluene, hν Only traces of TM on UPLC 
 
The methyl ester group and the hydroxy methylene group may be interfering with 
the cyclopropanation either directly through unfavorable steric interactions or 
indirectly by altering the conformation of piperidine ring. Therefore, to test the 
substituent effect on direct cyclopropanation of heterocycle, the methyl ester 4b was 
converted into nitrile 13 as outlined in Scheme 6. Conversion of methyl ester into 
the corresponding amide 14, followed by dehydration with trichloroacetyl chloride/ 
triethylamine afforded 15 in good yield.18 As showed in Table 4, the use of Corey’s 




product was isolated in very low yield (3%). Interestingly, implementation of 
Corey’s reaction conditions using dimethylaminophenylsulfoxonium methylide19 led 
to a slight improvement in yield (ca. 11%) that, however, was mitigated by the 
formation of a complicated mixture of byproducts. Hydrolysis of cyano group was 
accomplished by N-Boc deprotection to afford 1 with very low overall yield (3%) 
(Scheme 6).  
 
 
Scheme 6 - The effect of a linear substituent on the cyclopropanation of piperidine ring 
 
In a second approach to change the conformation of the piperidine ring to a more 
favorable one, the arecoline core was exchanged for a piperidone-like structure. The 
preparation of β−amido ester 19 from δ-valerolactam (16a) is well precedented20 
and is outlined in Scheme 7. Initial protection of δ-valerolactam as  
tert-butylcarbamate was carried out straightforwardly, followed by  
C-carboxymethylation to give 17. Subsequent introduction of the C-3/C-4 
unsaturation was carried out via selenation and intermediate syn-elimination. 
11% Dimethylaminophenylsulfoxonium 
methylide 
3% Corey reactant 
Yield of 13 Methylene sources 
Table 4 - Cyclopropanation conditions 
Trimethylsilyldiazomethane traces 
ClCH2I (Simmons-Smith)  traces 



































































Scheme 7 – Synthesis of  the  unsatured piperidone 19 
 
With 19 in hand, we began our investigation of its cyclopropanation. Also in this 
case Corey’s reaction conditions ((CH3)3SO+I-, NaH, DMSO) were found to be 
essential for the modest observed conversion (5%) to occur. Again, the use of 
dimethylaminophenylsulfoxonium methylide led to a slight improvement in yield 
(15%), but no further improvements were registered modifying the base, the solvent 







































Scheme 8 – From 19 to 1: a successful but inefficient methodology 
 
In order to validate the ability to access the desired β-amino acid 1 with this 




Attempts to selectively reduce the lactam in presence of the ester with LiBH4 or 
DIBAL gave no reaction. In an improved protocol21, 20 was reduced with lithium 
triethylborohydride to a diastereomeric mixture of the N-Boc aminals 21. Further 
reduction with triethylsilane and BF3·Et2O followed by acidic work-up gave 22 in 
50% overall yield from 20. Subsequent ester hydrolysis followed by N-deprotection 
gave 1 in excellent yield.   
The observed chemoselectivity in the reduction step to aminals 21 is explained on 
the basis of a six-membered transition state (Figure 2). Model was obtained with the 
Chem3D Ultra software.22 
 
 
Figure 2 - Six-membered transition state.  
 
The overall yield of this synthetic pathway did not exceed 2% due to the low 
efficiency of the cyclopropanation step. Whereas all the other synthetic steps of the 
achieved plan worked well, we sought an alternative route to the required bicyclic 
lactam 20 and then converted it into amino acid 1 as described above. 
We planned a de novo synthesis of 20 via reaction of a protected amino olefin with 
an activate dimethylmalonate followed by intramolecular cyclization (Scheme 9). As 
the amino group required eventual protection, 4-phtalimido 1-butene (25)23 was 
employed as starting material for our work. 
 












Scheme 9 - Retrosynthetic analysis 
 
The cyclopropyl derivative 24 could be obtained by insertion of a carbene on olefin 
25. We chose testing the ability of dimethyl dibromomalonate24 and dimethyl 







































Cu (3eq), I2 (0.033 eq),
DMSO, reflux, 2h
Rh(OAc)2 (5%),








Scheme 10 – De novo synthesis of intermediate lactam 20 
 
The copper-promoted insertion of dimethyl dibromomalonate at reported 
temperature led only to the formation of a small amount of 24 (31% yield). 
Unsatisfactory yields (13-29%) were obtained also at higher temperatures (150-175 
°C) under mw irradiation. Moreover it was found that the yield of 24 dropped 




conditions. On the other hand, the use of [Rh2(OAc)4] coupled with slow 
introduction of the dimethyl diazomalonate into the reaction mixture afforded a 
higher yield of 24 regardless of scale. The reaction required lower temperature (70 
°C) and afforded cyclopropyl diester 24 in 64% yield26 (Scheme 10). 
For the construction of azabicycloheptanyl skeleton we were encouraged by a 
Danishefsky communication27 of the spontaneous intramolecular cyclization of 
amino diester 24 after N-deprotection. Classical dephtaloylation conditions (1.1 
equiv of hydrazine monohydrate in methanol at reflux) gave only deprotected amine 
26 in 64% yield. Upon standing in neat form, partial cyclization (15-30%) to 27 was 








Table 5 - Cyclization 
Conditions Conversion to 27 (%) 
SiO2, MeOH, rt - 
SCX, CHCl3, rt - 
HCl/ MeOH, rt - 
AcOH/ MeOH, rt - 
MeOH, reflux 15 
MeOH, 100 °C mw - 
n-BuLi, THF, -78° C 20 
n-BuLi, THF, 0 °C Only degradation 
N2H4*H2O (5 eq.), MeOH, reflux Full conversion to 28 
 
Initial attempts to effect the total conversion of dephtaloylamine 26 into lactam 27 
afforded very low yields of the awaited compound, instead affording multiple 
products attributed to decomposition of starting material. Optimization efforts 
included the activation of 26 via the addition of additivies or treatment with a base in 
combination with temperature and solvent screening (Table 5). The most significant 




improvements in the efficiency of the reaction were realized employing an excess of 
hydrazine monohydrate (5 equiv) and running the reaction in refluxing MeOH; in 
those conditions, undesirable hydrolysis of ester group together with the efficient 
intramolecular cyclization was observed and carboxylic acid 28 was obtained in 
good yield (80%).  
With these results in hand, we next addressed direct conversion of 24 into lactam 27. 
Vigorously hydrazinolysis conditions (2.5 equiv of hydrazine in methanol at reflux 
for 18 h) provided β-amido ester 27 in 64% yield after crystallization. Finally, after 
N-protection as tert-butylcarbamate necessary for the subsequent chemoselective 
reduction to 22, ester hydrolysis and N-deprotection gave bicyclic β-amino acid 1 in 



















































In summary, we have achieved a practical approach to the synthesis of  
3-azabicyclo[4.1.0] heptane-1-carboxylic acid (1) starting from 4-phtalimido 1-
butene (25) via cyclopropanation of an appropriate olefine, intramolecular 
cyclization and chemoselective reduction. With the optimized synthetic route, 
nipecotic acid mimetic 1 was prepared in 7 steps with 14% overall yield (Scheme 
11).  
 
3.1.2  ISONIPECOTIC ACID  MIMIC 
 
In the light of the studies realized on the scaffold 1, the best way to synthesize the  
γ-amino acid 2 is the de novo synthesis of its molecular framework. Mori and 
coworkers reported the synthesis of a full protected derivative of 2 through 
intramolecular cyclization of the iodomethylen piperidine 29, deriving via  
















Scheme 12 - Retrosynthetic analysis 
 
We optimized that synthetic way in order to increase its overall yield. The starting 
α-haloester having internal double bond 33a was prepared from commercially 
available ethyl γ-aminobutyrate (31a) as outlined in Scheme 13. After N-protection 
as tert-butylcarbamate, classical alkylation with allylbromide afforded 32 in 
moderate yield. 
 




























































Scheme 14 - Synthesis of 3-aza-bicyclo[4.1.0] heptane-6-carboxylic acid  (2) 
 
It was not so easy to get the α-haloesters having amino group. Halogenation via 
ketene silyl acetal followed by reaction with bromine and subsequent treatment with 
potassium iodide gave 33a in 13% yield.29 Better results were obtained reacting 32 
with LDA at – 78 °C followed by treatment with I2 (57% yield). After changing the 
N-protecting group into phenyloxycarbamate (the Boc-protecting group allowed to 
prepare 33a in satisfactory yield, whilst phenyloxycarbonyl group was more suitable 
for the next steps and guaranteed higher yields) α-iodoester 30 was warmed with 
10% Pd(PPh3)4 at 65 °C in HMPA in the presence of proton-sponge  
(1,8-dimethylaminonaphtalene) as scavenger of hydrogen iodide to afford with 46% 
yield iododerivative 29 as unseparable diastereoisomeric mixture. The moderate 
yield of 29 was due to the formation of 7-membered ring 34, rationalized on the 




to give the fused three membered ring product 35 in moderate yield. Finally, 
hydrolysis of ester group followed by phenyloxycarbonyl group cleavage afforded 
the target compound 2 in good yield (Scheme 14). 
 
3.2 CONSTRAINED BIS-AMINES 
 
Constrained bis-amines are interesting as rigid scaffolds with two nitrogen atoms 
held at a well defined distance. Among these, 3-azabicyclo[3.1.0]hexylamine 38 has 
considered a privileged structure: besides being a key constituent of the highly 
active antibiotic trovafloxacin31, this rigid system mimics the piperazine ring of 


















Figure 3 - 3-azabicyclo[3.1.0]hexylamine 38 mimics  the piperazine ring of eperezolid 
 
In order to investigate the biological properties of these rigid systems, we prepared a 
variety of bicyclic bis-amines incorporating the amino-3-azabicyclo[3.1.0]hexane 



















Figure 4 – Conformationally restricted bis-amines 
 




Because of these scaffolds have to be used in focused drug-like subsets of 
compounds containing at least two different substituents on the two nitrogen atoms, 
these nitrogen atoms would have to be chemically addressable individually and 
selectively.  
 
3.2.1 3-(PHENYLMETHYL)-3-AZABICYCLO[4.1.0]HEPTAN-1-AMINE  
 
For the preparation of amine 37, we sought the synthetic route developed by 
Laroche and coworkers.33 The key step was the Ti(II)-mediated intramolecular 









Scheme 15 - Retrosynthetic analysis 
 
Starting nitrile 41 was readly prepared by alkylation of benzylamine first with 4-
bromo-1-butene and then with bromoacetonitrile. Intramolecular reductive 
cyclopropanation of 41 upon treatment with titanium isopropoxide and 
cyclohexylmagnesium chloride with subsequent addition of a Lewis acid, such as 
























3.2.2 APICAL BIS-AMINES 
 
The apical amino group on the bicyclic systems 38, 39 and 40 was envisioned to 












Scheme 18 - Retrosynthetic analysis 
 
The Curtius rearrangement using diphenylphosphoryl azide in refluxing toluene 
followed by treatment with benzyl alcohol introduced the requisite amino group at 
















































































Scheme 19 – The simple synthetic plans to 38, 39 and 40 
 




Compounds 45, 48 and 50 serve as useful synthetic fragments, given the differential 
protection of the two amino groups. For our pourpose, hydrogenation of the Cbz 
group on the primary amine was carried out, delivering monoprotected 38, 39 and 
40. 1H NMR determinations carried out on these substrates established that the 
Curtius rearrangement had proceeded with retention of configuration, as expected. 
 
3.3  EXPERIMENTAL SECTION 
 
Compound 4b. K2CO3 (18.3 g, 133 mmol) was added to arecoline hydrobromide (25 
g, 106 mmol) in 60 mL of H2O. After 30 min, the mixture was extracted with Et2O, 
the organic layers were dried (Na2SO4) and evaporated, and the resulting oil was 
dissolved in toluene (120 mL). ACE-Cl (14 mL, 128 mmol) was added slowly and 
the mixture was heated to reflux. After 16 h, HCl (100 mL, 0.1 N) was added and 
the mixture was extracted with Et2O. The organic layers were dried (Na2SO4), 
filtered and evaporated under vacuum. The resulting carbamate was dissolved in 
MeOH (100 mL) and heated to reflux. After 2 h, the solvent was evaporated and the 
resulting amine was dissolved in 150 mL DCM and cooled to 0 °C. TEA (16.5 mL, 
118 mmol) and Boc2O (31.7 g, 145 mmol) were added. After 24 h, HCl (100 mL, 1 
M) was added and the mixture was extracted with DCM. The organic layers were 
washed with sat.d aq. NaHCO3 solution, dried (Na2SO4), filtered, evaporated and 
purified by flash chromatography, eluting with Etp/EtOAc=9:1, to give the 
carbamate 4b (20 g, 78%) as an oil that crystallized at low temperature:  
mp 29-31 °C. 1H NMR spectrum was superimposible to that reported in literature.35 
 
Compound 9a. 2M solution of TMSCHN2 in Et2O, (622 µl, 1.24 mmol) was added 
to a solution of 4b (100 mg, 0.414 mmol) in 4 mL of dry toluene. After stirring at 
room temperature for 1 h, the mixture was refluxed till the reaction was complete 
(UPLC monitoring) and the solvent removed under vacuum. The remaining crude 
material was purified by SPE-Si column (5 g, grad. Hexane to Hexane/EtOAc=9:1) 




δ 6.34 (d, 1H), 3.91 (d, 1H), 3.76 (s, 3H), 3.69 (dd, 1H), 3.52-3.59 (m, 1H), 3.34-
3.51 (m, 1H), 3.06-3.23 (m, 1H), 1.94-2.08 (m, 1H), 1.65-1.82 (m, 1H), 1.44, 1.47 
(2s, 9H), 0.22 (s, 9H). UPLC/MS (ES+), m/z: found 356 [MH+], C16H29N3O4Si 
requires 355. Rt: 0.80 min. 
 
Compound 9b. A solution of hydrazone 9a (40 mg, 0.113 mmol) in 4 mL of MeOH 
was stirred at room temperature for 16 h. Solvent was evaporated under vacuum to 
afford pyrazoline 9b (27 mg, 86%) which did not need any purification. 1H NMR 
(400 MHz) δ 6.69 (bd, 1H), 6.01-6.14 (m, 1H), 3.79 (s, 3H), 3.30-3.79 (m, 4H), 
1.94-2.06 (m, 1H), 1.63-1.76 (m, 1H), 1.46 (s, 9H). UPLC/MS (ES+), m/z: found 
284 [MH+], C13H21N3O4 requires 283. Rt: 0.59 min. 
 
Compounds 11a and 11b. K2CO3 (68.3 mg, 0.494 mmol) was added to a solution of 
pyrazoline 9b (70 mg, 0.247 mmol) in 3 mL of EtOH. The mixture was refluxed 
under nitrogen atmosphere for 15 h. Volatiles were evaporated under vacuum to 
afford a mixture of compounds 11a and 11b (44.6 mg, 40%), identified by UPLC 
analysis. UPLC/MS (ES+), m/z: found 226 [MH+], C11H19N3O2 requires 225.  
Rt: 0.45 min and 0.53 min. 
 
Compound 12. A solution of compounds 11 (44.6 mg, 0.198 mmol) in 5 mL of 
toluene was refluxed for 24 h. Volatiles were evaporated under vacuum to afford the 
crude product 12 (5 mg, 13%) which no need any purification.  UPLC/MS (ES+), 
m/z: found 198 [MH+], C11H19N3O2 requires 197. Rt: 0.62 min. 
 
Compound 4c. To a solution of monohydrate LiOH (1.19 g, 28.2 mmol) in 10 mL of 
H2O was added ester 4b (3.42 g, 14.2 mmol) diluted in 11 mL of a mixture 
MeOH/THF=10:1 and the mixture was stirred at room temperature. After 4h the 
reaction was complete. The reaction mixture was acidificated with 1N aq. HCl 
solution, diluted with H2O and backextracted three times with DCM. The combined 




organics were dried (Na2SO4), filtered and concentrated under vacuum to afford the 
acid 4c (3.20 g, quantitative) which did not need any purification. 1H NMR (400 
MHz) δ 7.40 (bs, 1H), 4.18 (bs, 4H), 2.34 (bs, 2H), 1.58 (s, 9H). UPLC/MS (ES+), 
m/z: found 228 [MH+], C11H17NO4 requires 227. Rt: 0.62 min. 
 
Compound 14. Carboxylic acid 4c (550 mg, 2.42 mmol), DIPEA (1.86 ml, 10.65 
mmol) and TBTU (1.71 g, 5.32 mmol) were dissolved in 12 mL of DMF and the 
solution was stirred at room temperature for 1 h. HMDS (859 mg, 5.32 mmol) was 
added and stirring was continued for further 18 h. The mixture was diluted with 
EtOAc and washed with H2O and with sat.d aq. NH4Cl solution. The aqueous layers 
were backextracted three times with EtOAc. The combined organic layers were 
dried (Na2SO4), filtered and concentrated under vacuum. Purification of the crude 
residue by chromatography over SPE-Si column (25 g, grad. Hexane/Acetone=95:5 
to Hexane/ Acetone=1:1) afforded the pure amide 14 (260 mg, 48%). 1H NMR (400 
MHz) δ 6.70 (bs, 1H), 5.48 (bs, 2H), 4.17 (dd, 2H), 3.51 (t, 2H), 2.27-2.36 (m, 2H), 
1.50 (s, 9H). UPLC/MS (ES+), m/z: found 227 [MH+], C11H18N2O3 requires 226. 
Rt: 0.54 min. 
 
Compound 15.  To a stirred mixture of 14 (1.10 g, 4.87 mmol), TEA (1.35 mL, 9.74 
mmol) in 8 mL of dry DCM was added dropwise trichloroacetyl chloride (0.974 g, 
5.36 mmol) dissolved in 3 mL of dry DCM, between 0-5 °C. After the addition was 
finished, the mixture was treated with ice-cooled water, 5% aq. NaOH solution, 5% 
HCl solution and finally with H2O. The organic solution was dried (Na2SO4), 
filtered and concentrated under vacuum to afford nitrile 15 (1.0 g, 98%) as yellow 
pale oil. 1H NMR (400 MHz) δ 6.77 (bs, 1H), 4.06 (bs, 2H), 3.53 (t, 2H), 2.33 (bs, 
2H), 1.49 (s, 9H). UPLC/MS (ES+), m/z: found 209 [MH+], C11H16N2O2 requires 





Compound 13. NaH (17.3 mg, 0.720 mmol, 60% oil dispersion) was added 
portionwise to a solution of dimethylaminophenylsulfoxonium methylide (130 mg, 
0.480 mmol) in 2 mL of DMSO. After 20 min a solution of 15 (100 mg, 0.480 
mmol) in 2 mL of DMSO was added and the mixture was stirred at room 
temperature for 18 h. Brine was added and the reaction extracted four times with a 
mixture Hexane/EtOAc=1:1. Combined organics were dried (Na2SO4), filtered and 
concentrated under vacuum. Purification of the crude residue by chromatography 
over SPE-Si column (2 g, grad. Hexane to Hexane/Acetone=95:5) gave the pure 13 
(12.7 mg, 11%).1H NMR (400 MHz) δ 3.97-4.30 (m, 1H), 3.45-3.70 (m, 2H), 2.88-
3.03 (m, 1H), 1.99-2.13 (m, 1H), 1.67-1.84 (m, 2H), 1.57 (s, 9H), 1.47 (dd, 1H), 
0.83 (t, 1H). UPLC/MS (ES+), m/z: found 223 [MH+], C12H18N2O2 requires 222. 
Rt: 0.70 min. 
 
Hydrolysis of 13. In a 5 mL microwave vial was added 13 dissolved in 1 mL of 37% 
aq. HCl. The mixture was heated to 150 °C for 10 minutes by mw irradiation. 
Volatiles were removed under vacuum to afford quantitatively the crude 1 as 
hydrochloride salt. 1H NMR (400 MHz, D2O) δ 4.27 (d, 1H), 3.11-3.19 (m, 1H), 
3.04 (d, 1H), 2.66-2.77 (m, 1H), 2.22 (ddd, 1H), 1.91-2.03 (m, 2H), 1.66 (dd, 1H), 
1.07 (dd, 1H). 
 
Compound 16b. To a solution of δ-valerolactam (1.02 g, 10.3 mmol) in 20 mL of 
acetonitrile was added DMAP (122 mg, 1.0 mmol) followed by a solution of Boc2O 
(2.50 g, 11.5 mmol) in 10 mL of the same solvent. The colorless reaction mixture 
was stirred at room temperature for 2 h. The resulting orange reaction mixture was 
concentrated in vacuo and the crude was taken up in Et2O. The mixture was washed 
with 1N aq. HCl solution. The organic phase was dried (Na2SO4), filtered and 
concentrated under vacuum. Purification of the crude residue by chromatography 
over silica gel (Hexane/EtOAc= 6:4) afforded the pure 16b (1.71 g, 83%) as a white 
crystalline powder. mp: 31-33 °C. 1H NMR (400 MHz) δ 3.50-3.57 (m, 2H), 2.34-




2.44 (m, 2H), 1.66-1.76 (m, 4H), 1.40 (s, 9H). 13C NMR (75 MHz) δ 171.0, 152.4, 
82.4, 46.0, 34.6, 27.7, 22.5, 20.2. UPLC/MS (ES+), m/z: found 200 [MH+], 
C10H17NO3 requires 199. Rt: 0.61 min. 
 
Compound 17. 2M LDA solution in heptane/THF (5.47 ml, 10.94 mmol) was 
slowly added  at -78 ºC to a solution of 16b (1.677 g, 8.42 mmol) in 10 mL of dry 
THF. The resulting solution was stirred at -78 °C for 30 min, then methyl 
chloroformate (0.978 ml, 12.62 mmol) was added and the reaction mixture was 
allowed to warm to room temperature over 3 h. Sat.d aq. NH4Cl solution was added, 
followed by EtOAc and H2O. The layers were separated and the aqueous phase was 
extracted twice with EtOAc. The combined organics were dried (Na2SO4), filtered 
and concentrated under vacuum. Purification of the crude residue by 
chromatography over SPE-Si column (25 g, Cyclohexane/Acetone= 95:5) afforded 
the pure 17 (1.310 g, 61%) as a pale yellow oil. 1H NMR (400 MHz) δ 3.79 (s, 3H), 
3.71 (t, 2H), 3.54 (dd, 1H), 2.05-2.26 (m, 2H), 1.92-2.04 (m, 1H), 1.77-1.89 (m, 
1H), 1.54 (s, 9H). 
 
Compound 18. 2M LDA solution in heptane/THF (3.31 ml, 6.62 mmol) was added 
dropwise at -78 ºC to a solution of 17 (1.31 g, 5.09 mmol) in 10 mL of dry THF. 
After 30 min a solution of PhSeCl (1.268 g, 6.62 mmol) in 3 mL of dry THF was 
added and stirring at -78 ºC was continued for further 1 h. The mixture was then 
allowed to warm to 0 ºC over 2 h. Sat.d aq. NH4Cl solution and EtOAc were added 
and the layers were separated. The organic layer was further washed with brine, then 
dried (Na2SO4), filtered and concentrated under vacuum. Purification of the crude 
residue by chromatography over SPE-Si column (25 g, grad. Cyclohexane to 
Cyclohexane/AcOEt=9:1) gave the pure 18 (810 mg , 39%). 1H NMR δ 7.65 (d, 
2H), 7.41 (t, 1H), 7.27-7.32 (m, 2H), 3.76 (s, 3H), 3.54-3.66 (m, 1H), 3.41-3.52 (m, 
1H), 2.28 (dt, 1H), 1.95-2.06 (m, 1H), 1.79-1.90 (m, 1H), 1.64-1.77 (m, 1H), 1.54 (s, 
9H). UPLC/MS (ES+), m/z: found 357 [MH+-56(Boc)], C18H23NO5Se requires 412. 




Compound 19. To a solution of 18 (310 mg, 0.75 mmol) in 4 mL of DCM at 0 °C 
was added dropwise a 30% aqueous H2O2 solution (5.76 mL, 57.0 mmol). The 
mixture was stirred at 0 °C for 4 h before being quenched with aq. 1N HCl solution. 
The aqueous layer was extracted three times with DCM and the combined organics 
were washed with a sat.d aq. NaHCO3 solution, dried (Na2SO4), filtered and 
concentrated under vacuum. Compound 19 (160 mg, 84%) was obtained as yellow 
pale oil. 1H NMR (400 MHz) δ 7.55 (t, J= 3.8 Hz, 1H), 3.88 (t, J = 6.2 Hz, 2 H), 
3.85 (s, 3H), 2.54 (td, J= 6.3 Hz, J= 4.4 Hz, 2 H), 1.54 (s, 9 H).  
 
Compound 20. NaH (28.4 mg, 1.185 mmol, 60% oil dispersion) was added 
portionwise to a solution of dimethylaminophenylsulfoxonium methylide (193 mg, 
0.711 mmol) in 3 mL of DMSO. After 20 min a solution of 19 (121 mg, 0.474 
mmol) in 3 mL of DMSO was added and the stirring was continued for further 3 h. 
Brine was added and the reaction extracted three times with EtOAc. The combined 
organics were dried (Na2SO4), filtered and concentrated in vacuo. Purification of the 
crude residue by chromatography over SPE-Si column (2 g, grad. Hexane to 
Hexane/EtOAc=95:5) afforded the pure 20 (19.1 mg, 15%) as yellow pale oil. 1H 
NMR spectrum of isolated compound was superimposible to that described below.  
 
Compound 24. To a solution of 25 (5.28 g, 26.2 mmol) in 50 mL of chlorobenzene 
was added Rh2(OAc)4 (0.580 g, 1.31 mmol). The suspension was warmed to an 
internal temperature of +60 ºC and dimethyl diazomalonate (6.64 g, 42.0 mmol) was 
added dropwise keeping the Ti below +70 ºC. After 1 h, dimethyl diazomalonate 
(6.64 g, 42.0 mmol) was added dropwise keeping the Ti below  
+70 ºC and the reaction mixture was stirred for further 1 h. The suspension was 
cooled to room temperature, diluted with DCM and filtered from catalyst. Solvent 
was partially removed under vacuum; crude material was purified by flash 
chromatography (Cyclohexane/AcOEt 6:4) to afford cyclopropane derivative 24 
(5.55 g, 64%) as off-white solid: mp =124-126 °C. 1H NMR (400 MHz) δ 7.82-7.89 
(m, 2H), 7.69-7.76 (m, 2H), 3.76-3.87 (m, 5H), 3.73 (s, 3H), 1.90-2.01 (m, 1H), 




1.63-1.86 (m, 2H), 1.37-1.48 (m, 2H). 13C NMR (100 MHz) δ 170.4, 168.3, 168.2, 
134.0, 132.1, 123.2, 52.7, 52.6, 37.0, 33.7, 27.8, 25.9, 20.5. UPLC/MS (ES+), m/z: 
found 332 [MH+], C17H17NO6 requires 331. Rt: 0.68 min. 
 
Compound 26. Hydrazine monohydrate (0.112 mL, 3.59 mmol) was added to a 
solution of diester 24 (1.08 g, 3.27 mmol) in 40 mL of MeOH and the mixture was 
heated to reflux. After 18 h the mixture was cooled to room temperature and the 
solvent was partially evaporated under vacuum. The residue was dissolved in DCM; 
precipitate was filtered off and washed with DCM. The organic layers were 
combined and the solvent evaporated under vacuum to afford 26 (420 mg, 64%) as a 
yellow pale oil. UPLC/MS (ES+), m/z: found 202 [MH+], C7H9NO3 requires 201. 
Rt: 0.34 min. 
 
Compound 28. Hydrazine monohydrate (0.51 mL, 16.3 mmol) was added to a 
solution of 26 (1.08 g, 3.27 mmol) in 50 mL of MeOH and the mixture was heated 
to reflux. After 18 h the mixture was cooled to room temperature and the solvent 
was partially evaporated under vacuum. The residue was dissolved in DCM; 
precipitate was filtered off and washed with DCM. The organic layers were 
combined and the solvent evaporated under vacuum to afford the crude aminoacid 
28 (405 mg, 80%) as tallow pale oil. 1H NMR (400 MHz) δ 12.31 (s, 1H), 5.76-5.97 
(m, 1H), 3.12-3.31 (m, 2H), 2.67 (t, 1H), 2.02-2.25 (m, 2H), 1.76 (dd, 1H), 1.68 (dd, 
1H).  
 
Compound 27. Hydrazine monohydrate (0.257 ml, 8.19 mmol) was added to a 
solution of diester 24 (1.085 g, 3.27 mmol) in 40 mL of MeOH and the mixture was 
heated to reflux. After 18 h the mixture was cooled to room temperature and the 
solvent was partially evaporated under vacuum. The residue was dissolved in DCM; 
precipitate was filtered off and washed with DCM. The organic layers were 




residue from Et2O/MeOH= 95:5 afforded 27 (353 mg, 69%) as off-white solid:  
mp= 133-135 °C. 1H NMR (400 MHz) δ 6.58 (bs, 1H), 3.77 (s, 3H), 3.21-3.32 (m, 
1H), 3.04-3.15 (m, 1H), 2.09-2.21 (m, 1H), 1.91-2.00 (m, 2H), 1.88 (dd, J= 4.0 Hz,  
J= 8.0 Hz, 1H), 1.46 (t, J= 4.0 Hz, 1H). 13C NMR (100 MHz) δ 170.5, 168.6, 52.7, 
38.0, 28.0, 24.7, 20.3, 16.4. UPLC/MS (ES+), m/z: found 170 [MH+], C8H11NO3 
requires 169. Rt: 0.37 min. 
 
Compound 20. To a solution of 27 (400 mg, 2.364 mmol) in 15 ml of a 2:1 mixture 
toluene/ DCM was added DMAP (433 mg, 3.55 mmol) followed by Boc2O (0.659 
mL, 2.84 mmol). The resulting mixture was heated to reflux for 2 h, diluted with 
DCM and washed with brine. The organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash chromatography (DCM) of the crude 
residue afforded 20 (0.57 g, 90%) as a yellow pale oil. 1H NMR (400 MHz) δ 3.76-
3.85 (m, 4H), 3.45-3.54 (m, 1H), 2.15-2.32 (m, 1H), 1.98-2.08 (m, 1H), 1.86-1.97 
(m, 2H), 1.52-1.57 (m, 9H), 1.49 (t, J= 4.0 Hz, 1H). 13C NMR (100 MHz) δ  170.2, 
167.1, 152.8, 83.5, 52.8, 42.7, 31.2, 28.0, 25.5, 22.6, 19.0. UPLC/MS (ES+), m/z: 
found 270 [MH+], C13H19NO5 requires 269. Rt: 0.63 min. 
 
Compound 22. 1.0 M Superhydride solution (2.495 ml, 2.495 mmol) was added 
over 30 min to a solution of lactam 20 (0.56 g, 2.08 mmol) in 5 mL of THF cooled 
to -10 ºC. After 2 h at 0 ºC, Superhydride (0.500 mL) was added and the solution 
was stirred for further 2 h. The reaction mixture was quenched with H2O and 
extracted three times with EtOAc. The organic layer was dried (Na2SO4), filtered 
and concentrated under vacuum. Purification by flash chromatography 
(Cyclohexane/EtOAc=6:4) afforded 21 (0.36 g, 64%) as unseparable mixture of 
diastereoisomeric aminals. 
A solution of aminals 21 (250 mg, 0.92 mmol) and triethylsilane (0.147 mL, 0.921 
mmol) in 8 mL of DCM was cooled to -78 ºC and BF3*OEt2 (0.117 mL, 0.921 
mmol) was then added dropwise under nitrogen atmosphere. After 30 min, more 




triethylsilane (0.147 mL, 0.921 mmol) and BF3*Et2O (0.117 mL, 0.921 mmol) were 
added and the resulting mixture was stirred for further 1.5 h at - 78 ºC. The reaction 
mixture was warmed to room temperature, diluted with DCM and washed with H2O. 
The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by flash chromatography (Cyclohexane/EtOAc=95:5) of the crude 
residue afforded 22 (0.19 g, 36% for two steps) as yellow pale oil. 1H NMR (400 
MHz) δ 3.82-4.12 (m, 2H), 3.66-3.74 (m, 3H), 3.51 (bs, 1H), 2.87-3.03 (m, 1H), 
1.94 - 2.08 (m, 1H), 1.66-1.86 (m, 2H), 1.44-1.53 (m, 9H), 1.41 (dd, J= 4.0 Hz,  
J= 12.0 Hz, 1H), 0.75 (dd, J= 4.0 Hz, J= 8.0 Hz, 1H). ESI m/z (relative intensity) 
278 ([M+ Na]+, 63), 200 (100), 182 (86).  
 
Compound 23. To a solution of LiOH (33.8 mg, 1.410 mmol) in 2 mL of H2O was 
added ester 22 (180 mg, 0.705 mmol) diluted in 3 mL of a mixture 
MeOH/THF=10:1 and the mixture was stirred at room temperature. After 3 h the 
reaction was complete. The reaction mixture was acidificated with 1N aq. HCl 
solution, diluted with H2O and backextracted with DCM (3 x 30ml). The organic 
layer was dried (Na2SO4), filtered and concentrated under vacuum to afford the 
awaited compound 23 (146 mg, 86%). 1H NMR (400 MHz) δ  3.94 (bs, 2 H), 3.72-
3.81 (m, 1H), 3.47 (bs, 1H), 2.94-3.04 (m, 1H), 1.96-2.10 (m, 1H), 1.72-1.85 (m, 
2H), 1.42-1.54 (m, 10H), 0.83 (dd, 1H). 13C NMR (100 MHz) δ 179.8, 156.0, 79.9, 
44.7, 38.5, 28.0, 26.7, 22.0, 20.9, 19.8. ESI m/z (relative intensity) 264 ([M+ Na]+, 
61), 186 (100).  
 
Compound 1. Compound 23 (100 mg, 0.415 mmol) was dissolved in 4 mL of a 
mixture 3:1 DCM/TFA. The solution was stirred at 0 ºC; after 45 min UPLC 
analysis showed that the reaction was complete. Solvents were evaporated under 
vacuum to afford compound 1 (95.2 mg, 90%) as trifluoroacetic salt, which did not 
need any purification. 1H NMR (400 MHz, D2O) δ 4.27 (d, 1H), 3.11-3.19 (m, 1H), 




1.07 (dd, 1H). 13C NMR (100 MHz) δ 176.6, 43.1, 38.1, 30.3, 21.2, 19.9, 18.6. 
UPLC/MS (ES+), m/z: found 142 [MH+], C7H11NO2 requires 141. Rt: 0.21 min. 
  
Compound 31b. To a solution of ethyl 4-aminobutanoate (31a) (3.76 g, 22.43 
mmol) and TEA (3.12 mL, 22.43 mmol) in 100 mL of acetonitrile was added Boc2O 
(5.38 g, 24.67 mmol) in one portion. The mixture was stirred 1.5 h at room 
temperature. Solvent was evaporated under vacuum and the residue was purified by 
SPE-Si column (50 g, grad. Cyclohexane to Cyclohexane/EtOAc=7:3) to afford the 
protected amine 31b (5.10 g, quantitative). 1H NMR (400 MHz) δ 4.63 (bs, 1H), 
4.15 (q, 2H), 3.03-3.31 (m, 2H), 2.36 (t, 2H), 1.73-1.99 (m, 2H), 1.45 (s, 9H), 1.27 
(t, 3H). UPLC/MS (ES+), m/z: found 232 [MH+], C11H21NO4 requires 231. Rt: 0.68 
min. 
 
Compound 32. Amine 31b (5.10 g, 22.07 mmol) was dissolved in 80 mL of dry 
DMF and the resulting solution was cooled to 0 °C. NaH (2.91 g, 121 mmol) was 
added; after 30 min AllBr (6.29 mL, 72.6 mmol) was added and the mixture was 
stirred under nitrogen atmosphere at room temperature for 1 h. Sat.d aq. NH4Cl 
solution was added and the mixture was extracted twice with EtOAc. Combined 
organic layers were dried (Na2SO4), filtered and concentrated under vacuum. Crude 
material was purified by SPE-Si column (50 g, grad. Cyclohexane to 
Cyclohexane/EtOAc=9:1) to afford 32 (1.734 g, 26%). 1H NMR (400 MHz) δ 5.60-
5.96 (m, 1H), 4.98-5.24 (m, 2H), 4.13 (q, 2H), 3.81 (bs, 2H), 3.22 (bs, 2H), 2.29 (t, 
2H), 1.77-1.93 (m, 2H), 1.46 (s, 9H), 1.26 (t, 3H). UPLC/MS (ES+), m/z: found  
172 [MH+-100(Boc)], C14H25NO4 requires 271. Rt: 0.81 min. 
 
Compound 33a. 2M LDA solution in heptane/THF (5.33 ml, 9.59 mmol) was added 
via a syringe to a solution of 32 (1.73 g, 6.39 mmol) in 50 mL of dry THF cooled to 
– 78 °C. After being stirred for 30 min at – 78 °C, the reaction mixture was treated 
with finely crushed iodine (2.11 g, 8.31 mmol) crystals and then stirred at – 78 °C 




for 1 h. Brine was added to the solution; aqueous layer was extracted with EtOAc. 
Combined organic layers were dried (Na2SO4), filtered and concentrated under 
vacuum. Purification by SPE-Si column (25 g, grad. Cyclohexane to Cyclohexane/ 
EtOAc=95:5) of the crude residue afforded the pure 33a (1.44 g, 57%). 1H NMR 
(400 MHz) δ 5.64-5.92 (m, 1H), 5.02-5.22 (m, 2H), 4.32 (t, 1H), 4.22 (q, 2H), 3.80 
(bs, 2H), 3.25-3.44 (m, 1H), 3.11-3.26 (m, 1H), 2.01-2.40 (m, 2H), 1.47 (s, 9H), 
1.30 (t, 3H). UPLC/MS (ES+), m/z: found 298 [MH+-100(Boc)], C14H24INO4 
requires 397. Rt: 0.92 min. 
 
Compound 30. To a solution of 33a (1.04 g, 2.61 mmol) in 6 mL of DCM cooled at 
0 °C was added TFA (2 mL, 26.0 mmol). The reaction mixture was stirred at 0 °C 
for 1 h, then volatiles were evaporated under vacuum. Crude residue was dissolved 
in 3 mL of acetone and potassium carbonate (0.722 g, 5.22 mmol) and phenyl 
chloroformate (0.426 mL, 3.39 mmol) were added. The reaction mixture was stirred 
at room temperature for 2 h. Solvent was evaporated under vacuum; the residue was 
dissolved in H2O. The aqueous layer was backextracted twice with DCM. Combined 
organic layers were dried (Na2SO4), filtered and concentrated under vacuum. 
Purification of the crude residue by SPE-Si column (20 g, grad. Cyclohexane to 
Cyclohexane/EtOAc=85:15) afforded the pure 30 (544 mg, 50%). 1H NMR (400 
MHz) δ 7.38 (t, 2H), 7.22 (t, 1H), 7.05-7.18 (m, 2H), 5.74-6.10 (m, 1H), 5.18-5.36 
(m, 2H), 4.32-4.59 (m, 1H), 4.08-4.33 (m, 2H), 3.89-4.10 (m, 2H), 3.19-3.72 (m, 
2H), 2.40-2.59 (m, 1H), 2.15-2.38 (m, 1H), 1.28 (t, 3H). UPLC/MS (ES+), m/z: 
found 418 [MH+], C16H20INO4 requires 417. Rt: 0.87 min.  
 
Compound 29. To a solution of palladium tetrakis (0.085 g, 0.074 mmol) in 10 mL 
of HMPA was added 30 (1.06 g, 2.54 mmol) and Proton-Sponge (0.987 g, 4.60 
mmol) at room temperature under nitrogen atmosphere. The solution was heated to 
80 °C for 2 h. EtOAc was added; the organic layer was washed with 1N aq. HCl 
solution and brine, dried (Na2SO4), filtered and concentrated under vacuum.  The 




Cyclohexane/EtOAc=85:15) to give 29 (483.3 mg, 46%) as diastereoisomeric 
mixture. UPLC/MS (ES+), m/z: found 418 [MH+], C16H20INO4 requires 417. Rt: 
0.75 min. 
 
Compound 35. To a solution of 29 (227 mg, 0.544 mmol) in 4 mL dry DMSO was 
added DBU (0.172 mL, 1.143 mmol). Reaction mixture was stirred at 90 °C over 
night. EtOAc was added to the solution: the organic layer was washed with 1N aq. 
HCl solution and brine, dried (Na2SO4), filtered and concentrated under vacuum. 
Purification of the crude residue by SPE-Si column (5 g, grad. Cyclohexane to 
Cyclohexane/ EtOAc=9:1) gave the pure 35 (67.3 mg, 43%). 1H NMR (400 MHz) 
δ 7.37 (t, 2H), 7.21 (t, 1H), 7.11 (dd, 2H),  4.16 (q, J= 7.4 Hz, 2H), 3.86-4.13 (m, 
1H), 3.52-3.88 (m, 2H), 3.08-3.40 (m, 1H), 2.57-2.79 (m, 1H), 1.85-1.98 (m, 1H), 
1.82 (bs, 1H), 1.47-1.58 (m, 1H), 1.28 (t, J= 7.4 Hz, 3H), 0.89 (bs, 1H).  
 
Compound 36. To a solution of LiOH (15 mg, 0.626 mmol) in 1 mL of H2O was 
added ester 35 (46 mg, 0.171 mmol) dissolved in 1.1 mL of a mixture 
MeOH/THF=10:1. The mixture was stirred at room temperature for 2 h, then 
volatiles were evaporated under vacuum. Residue was dissolved in DCM and 
organic layer was washed with 1N aq. HCl solution, then dried (Na2SO4), filtered 
and evaporated under vacuum to afford the crude acid 36 (34.7 mg, 84%), that did 
not need any purification. 1H NMR (400 MHz) δ 7.37 (t, 2H), 7.21 (t, 1H), 7.11 (dd, 
2H), 3.89 (dd, 1H), 3.35-3.63 (m, 2H), 2.89-3.06 (m, 1H), 2.53 (dt, 1H), 1.71-1.87 
(m, 2H), 1.54 (dd, 1H), 0.82 (dd, 1H). 
 
Compound 2. LiOH (45 mg, 1.8 mmol) was added to a solution of acid 36 (15 mg, 
0.051 mmol) in 3 mL of toluene. The reaction mixture was refluxed for 18 h. After 
cooling to room temperature, the suspension was filtered from salts and volatiles 
evaporated under vacuum to afford the crude amino acid 2 (6.9 mg, quantitative), 




which did not need any purification. UPLC/MS (ES+), m/z: found 142 [MH+], 
C7H11NO2 requires 141. Rt: 0.17 min. 
 
Compound 42. A solution of benzylamine (7.56 mL, 69.2 mmol), 4-bromo-1-butene 
(1.50 mL, 14.81 mmol) and EtOH (10 mL) was deoxygenated with nitrogen and 
treated with NaI (10 mg, 0.067 mmol) at room temperature. The resulting solution 
was heated at 92 ºC for 3 h, then cooled to room temperature and partitioned 
between DCM and 1N aq. NaOH solution. The layers were separated and the 
aqueous phase was extracted with DCM. The combined organic layers were dried 
(Na2SO4), filtered and concentrated under vacuum. The crude residue was purified 
by SPE-Si column (25 g, Cyclohexane/EtOAc=1:1) to afford the pure 42 (2.39 g, 
quantitative). 1H NMR (400 MHz) δ 7.31-7.40 (m, 4H), 7.22-7.31 (m, 1H), 5.72-
5.89 (m, 1H), 4.98-5.18 (m, 2H), 3.82 (s, 2H), 2.73 (t, 2H), 2.25-2.36 (m, 2H).  
 
Compound 41. To a solution of amine 42 (1.49 g, 9.24 mmol) in 80 mL of 
acetonitrile were added in sequence potassium carbonate (1.92 g, 13.86 mmol) and 
bromoacetonitrile (1.93 mL, 27.7 mmol). The reaction mixture was refluxed for 4 h. 
The mixture was concentrated under vacuum. The residue was dissolved in DCM 
and organic layer was washed with H2O, then dried (Na2SO4), filtered and 
concentrated under vacuum. Purification of the crude residue by SPE-Si column (25 
g, grad. Cyclohexane/EtOAc=7:3 to Cyclohexane/EtOAc=3:7) gave the pure 41 
(1.759 g, 95%). 1H NMR (400 MHz) δ 7.28-7.41 (m, 5H), 5.77-5.92 (m, 1H), 5.04-
5.18 (m, 2H), 3.70 (s, 2H), 3.32-3.57 (m, 2H), 2.66-2.80 (m, 2H), 2.28-2.43 (m, 2H). 
UPLC/MS (ES+), m/z: found 201 [MH+], C13H16N2 requires 200. Rt: 0.80 min. 
 
Compound 37. To a solution of amine 41 (500 mg, 2.496 mmol) in 20 mL of Et2O 
were added successively Ti(Oi-Pr)4 (0.805 mL, 2.75 mmol) and 
cyclohexylmagnesium chloride (2.75 mL, 5.49 mmol). After stirring for 45 min, 




period of 45 min. 1N aq. NaOH solution was added and the mixture was extracted 
with Et2O. The combined ether layers were dried (Na2SO4), filtered and 
concentrated under vacuum. Purification of the crude residue by SPE-Si column  
(10 g, grad. Cyclohexane/EtOAc=9:1 to EtOAc, then Acetone) afforded the pure 37 
(156.3 mg, 31%). 1H NMR (400 MHz) δ ppm 7.21-7.38 (m, 5H), 3.43-3.48 (m, 2H), 
3.01 (d, J= 10.4 Hz, 1H), 2.37-2.51 (m, 1H), 2.22 (d, J= 10.4 Hz, 1H), 1.95 (dt,  
J= 17.5 Hz, J= 5.2 Hz, 2H), 1.53-1.76 (m, 3H), 0.91-1.06 (m, 1H), 0.62-0.74 (m, 
2H). UPLC/MS (ES+), m/z: found 203 [MH+], C13H18N2 requires 202. Rt: 0.23 min. 
 
Ester hydrolysis. To a solution of LiOH (1.41 mmol) in 2 mL H2O was added ester 
(0.705 mmol) diluted in a mixture MeOH/THF=10:1 and the mixture was stirred at 
room temperature. After 3 h the reaction was complete. The reaction mixture was 
acidificated with 1N aq. HCl solution, diluted with H2O and backextracted with 
DCM. The organic layer was dried (Na2SO4), filtered and concentrated under 
vacuum to afford awaited carboxylic acid which was used for successive step 
without further purification. 
Data for compound 44. quantitative, 1H NMR (400 MHz) δ 3.72 (bd, 1H), 3.64 (bd, 
1H), 3.38-3.59 (m, 2H), 2.12-2.17 (m, 2H), 1.52 (t, 1H), 1.44 (s, 9H). UPLC/MS 
(ES+), m/z: found  228 [MH+], C11H17NO4 requires 227. Rt: 0.58 min. 
Data for compound 47. quantitative, 1H NMR (400 MHz, DMSO-d6) δ 3.72 (d, 1H), 
3.45-3.54 (m, 1H), 3.21-3.32 (m, 1H), 2.88-2.99 (m, 1H), 1.81-1.96 (m, 1H), 1.61-
1.71 (m, 1H), 1.51-1.59 (m, 2H), 1.39 (s, 9H), 1.27 (t, 1H). UPLC/MS (ES+), m/z: 
found  242 [MH+], C12H19NO4 requires 241. Rt: 0.61 min. 
 
General procedure for Curtius rearrangement. Carboxylic acid (2.0 mmol), TEA 
(6.03 mmol) and diphenyl azidophosphate (3.01 mmol) were dissolved in 15 mL of 
toluene and the resulting solution was heated to reflux for 2 h. After cooling to room 
temperature, benzyl alcohol (10.0 mmol) was added. The solution was heated to 
reflux for 2 h, then diluted with 50 mL of EtOAc. Organic layer was washed with 




1N aq. HCl solution and brine, dried (Na2SO4), filtered and concentrated under 
vacuum. Purification of the crude residue by SPE-Si column (20 g, grad. 
Cyclohexane to Cyclohexane/EtOAc=8:2) gave the pure N-Cbz protected amine. 
Data for compound 45. 62% yield, 1H NMR (400 MHz) δ 7.28-7.43 (m, 5H), 5.12 
(bs, 2H), 3.63-3.75 (m, 2H), 3.34-3.45 (m, 2H), 2.34-2.41 (m, 1H), 1.66-1.79 (m, 
2H), 1.44 (s, 9H). UPLC/MS (ES+), m/z: found 277 [MH+-56 (Boc)] C18H24N2O4 
requires 332. Rt: 0.75 min. 
Data for compound 48.  42% yield, 1H NMR (400 MHz) δ 7.28-7.41 (m, 5H), 5.12 
(bs, 2H), 3.88 (d, 1H), 3.46-3.64 (m, 1H), 3.22-3.45 (m, 1H), 2.85-3.06 (m, 1H), 
2.25-2.41 (m, 1H), 1.90-2.07 (m, 1H), 1.62-1.90 (m, 1H), 1.46 (s, 9H), 1.33-1.52 (m, 
1H), 1.11-1.32 (m, 1H). UPLC/MS (ES+), m/z: found 347 [MH+], C19H26N2O4 
requires 346. Rt: 0.78 min. 
Data for compound 50. 30% yield, 1H NMR (400 MHz, DMSO-d6) δ 7.26-7.42 (m, 
5H), 4.92-5.19 (m, 2H), 3.59 (dd, 1H), 3.15-3.42 (m, 2H), 2.68-2.84 (m, 1H), 2.36-
2.49 (m, 1H), 1.74-1.90 (m, 1H), 1.40-1.59 (m, 1H), 1.37 (s, 9H), 1.05-1.30 (m, 2H). 
UPLC/MS (ES+), m/z: found 347 [MH+], C19H26N2O4 requires 346. Rt: 0.79 min. 
 
General procedure of hydrogenation. Reactions were performed in the H-Cube™. 
A CatCart™ was washed with only MeOH, and a 2 mL solution of amine was 
flowed through the catalyst at 1 mL/min at room temperature and 1 bar until TLC 
monitoring showed the reaction was complete. The resulting solution was 
concentrated under vacuum to give the desired N-Boc protected bis-amine. 
Data for compound 38. quantitative, 1H NMR (400 MHz, C6D6) δ  1.10-1.25 (m, 
2H), 1.46 (s, 9H), 1.68 (t, J= 2.0 Hz, 1H), 1.71 (bs, 2 H), 3.10 (dd, J= 3.7 Hz,  
J= 10.4 Hz, 1H), 3.25 (dd, J=3.9 Hz, J= 10.9 Hz, 1H), 3.38 (d, J= 10.5 Hz, 1H), 
3.65 ppm (d, J=10.9 Hz, 1H). 13C NMR (100 MHz) δ 25.4, 26.2, 28.5, 35.5, 48.0, 
78.7, 154.2.  
Data for compound 39. quantitative, 1H NMR (400 MHz, DMSO-d6) δ 3.64 (d, 1H), 




(m, 1H), 1.46-1.62 (m, 1H), 1.39 (s, 9H), 0.92-1.11 (m, 2H). UPLC/MS (ES+), m/z: 
found  157 [MH+-56(Boc)], C11H20N2O2 requires 212. Rt: 0.52 min. 
Data for compound 40. quantitative, 1H NMR (400 MHz) δ 3.32-3.81 (m, 4H), 
2.71-2.87 (m, 1H), 2.34 (t, 1H), 1.84-1.97 (m, 1H), 1.55-1.68 (m, 1H), 1.44 (s, 9H), 
0.99-1.11 (m, 1H), 0.81-0.96 (m, 1H). UPLC/MS (ES+), m/z: found 157 [MH+-
56(Boc)], C11H20N2O2 requires 212. Rt: 0.44 min. 
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4     CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Medicinal chemistry focuses on the aspect related to the structural design, synthesis 
and identification of therapeutically interesting compounds, i.e. pharmaceuticals, as 
well as the molecular reasons of their mechanism of action, including the 
understanding of the factors involved in the structure-activity relationships, 
absorption, distribution, metabolism, elimination and toxicity. 
The molecular recognition of a drug in the biophase is resultant from intermolecular 
interactions with biomacromolecules, involving electrostatic forces, dispersion and 
hydrophobic interactions, hydrogen and covalent bonds. The spatial arrangement of 
structural subunits of micromolecule, responsible for these interactions with the 
complementary sites of the target bioreceptor, includes the pharmacophoric 
requisites for its recognition, and defines qualitatively the affinity and selectivity 
degree of drug-bioreceptor complex. 
In the recent literature, it is noticed great interest in the identification of molecular 
frameworks, which correspond to the minimum structural subunit, usual in several 
drugs or lead-compounds, able of providing ligand points for more than one type of 
bioreceptor. Since Evans first introduced the concept of privileged structure, 
privileged-based drug discovery has emerged as a fruitful approach in medicinal 
chemistry. Privileged scaffolds increase hit rates for biological targets of interest, 
leading to the discovery of other biologically active targets and generating leads 
with enhanced drug-like properties. Consequently, medicinal chemists value 
privileged structures as core scaffolds for viable starting points in exploration design 
and synthesis.  
Despite the identification of numerous recurring molecular frameworks in bioactive 
molecules, there is a restricted availability of privileged structures. Toward this 
concern, a subject of great fashination and importance, dealing with the need to 
identify novel chemotypes, have been addressed the studies conducted during this 




frequently occurring structural motifs. The development of efficient methodologies 
for the synthesis of the identified compounds has provided the suitable tools to open 
up an investigation about the behaviour of such a kind of molecules towards 
biological systems.  
Inspired by the literature reports describing numerous bioactive piperidine and 
piperazine Ph- and Bn-derivatives, as well as by the fundamental knowledge 
according to which several compounds of these series are included in drugs with 
central and peripheral neurotropic effects, a general route for the synthesis of 






























In the context of introducing conformational constraint one strategy may be the 
construction of cyclic systems, and, in particular, cyclopropyl analogues of non 
cyclopropyl containing structures. Following this approach, a program aimed to 
synthesize constrained bicyclic[x.1.0] heterocycles (Figure 2) has been started 
(Chapter 3). 





















The chemistry presented here has offered high-yielding and scalable routes for the 
preparation of a wide range of suitably protected building blocks. Because of the  
de novo approach of such synthetic methodologies, the strategies have demonstrated 
to be highly convergent as well, minimizing the number of synthetic steps. Given the 
possibility to have easy access to such molecules in large amount, further 
endeavours could be addressed to their employ as scaffolds for the synthesis of more 
complex structures for enhancing our understanding of their role in biological 
environments.  
